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Abstract
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HOSPITALIZATION RISK, AND HEALTHCARE UTILIZATION AMONG
MEDICARE PATIENTS WITH ATRIAL FIBRILLATION: A GROUP-BASED
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Introduction: Warfarin is the most commonly prescribed drug for stroke prevention among
Atrial Fibrillation (AF) patients, especially in older adult populations, but medication
nonadherence reduces its effectiveness in clinical practice. Group Based Trajectory Models
(GBTM) have been used to identify distinct patterns of adherence behavior related to various
medications and understand the patient characteristics associated with each trajectory. The
objectives of the study were: 1) Describe trajectories of warfarin adherence among Medicare AF
patients, 2) Assess impact of adherence trajectories on AF-related hospitalization, 3) Estimate the
AF-related direct costs for each adherence trajectory group.

Methods: We identified elderly AF patients initiating warfarin treatment during 2008-2010
using data from a random sample of Medicare beneficiaries. The study’s first aim is to classify
patients into different trajectory groups based on their monthly adherence patterns using a
Group-Based Trajectory Model (GBTM). A multinomial regression model was used to assess
associations between baseline characteristics and adherence trajectories. The second aim is to
evaluate the association between adherence trajectories and time to first hospitalization related to
stroke or bleeding event. Hospitalization events due to bleeding or stroke were identified using
corresponding ICD-9 codes, and a Cox proportional hazard model was performed. The third aim
of the study is to calculate AF-related direct medical costs associated with each trajectory group.
SASv9.4 was used for analysis.
Results: Among 3,246 beneficiaries who met inclusion criteria, six adherence trajectories were
identified: 1) rapid-decline non-adherence group (11.5%), 2) moderate non-adherence group
(24%), 3) rapid-decline then increasing adherence group (6.8%), 4) moderate-decline nonadherence group (8.2%), 5) slow-decline non-adherence group (24.3%), and 6) perfect adherence
group (25.3%). Even though no statistical significances were found in the hazard of
hospitalization among the adherence groups, there were higher odds of hospitalization among the
lower adherence groups compared to perfect adherence group. Outpatient and monitoring costs
were significantly higher in the lower adherence trajectories compared to perfect adherence
group.
Conclusion: The GBTM is considered an innovative methodological approach that can be
applied to longitudinal medication adherence data and account for the dynamic nature of
adherence behavior in a better way than traditional adherence measures.

Chapter 1: Introduction
1.1 Introduction
Medication non-adherence is a major obstacle to improving healthcare outcomes. Poor
medication adherence is associated with numerous adverse health outcomes.1 Older adults,
patients with critical conditions, and those treated with medications with narrow therapeutic
windows are at increased risk for non-adherence related adverse events.2
Atrial Fibrillation:
Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia in clinical
practice.3 The condition affects more than 3 million Americans, and this figure is projected to
increase to 8 million by 2050.4 Approximately 70% of AF patients are between the age of 65 and
85 years.5 AF is a major risk factor for ischemic stroke (IS). Patients with AF are five times
more likely to develop IS than those without AF.3 Risk of IS increases in AF patients with
advancing age and the presence of other cardiovascular diseases, including hypertension, heart
failure, diabetes mellitus, and history of previous stroke or transient ischemic attack (TIA).4
Stroke contributes to substantial morbidity and mortality among the AF population. AF
patients who experience a stroke have increased mortality rates relative to those who do not.6
Moreover, strokes may cause an array of disabilities, such as vision impairment, inability to walk
without assistance, cognitive deficits, and depression. Stroke complications are associated with a
notable socioeconomic burden on both individuals and the healthcare system. In the
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United States, the mean lifetime cost per patient with an IS has been estimated at $140,048.6
Inpatient care is considered to be the main driver of stroke-related costs, accounting for 70% of
costs in the first year after a stroke.6 After the first year of survival, costs of lost productivity and
rehabilitation can be significant. According to the U.S. Centers for Disease Control and
Prevention (CDC), the stroke costs United States 34.6 billion dollars annually.7
Warfarin:
Warfarin, a vitamin K antagonist, has long been the most common treatment for
preventing stroke in AF patients. Several clinical trials have shown warfarin to be effective in
decreasing stroke by up to 64% compared to placebo, and it has been associated with reductions
in mortality among AF patients.8 Effective treatment with warfarin requires patients to be
maintained within a narrow International Normalized Ratio (INR) range between 2 to 3.
Maintenance of that range requires regular INR monitoring and potential dosing changes due to
the pharmacokinetic properties of warfarin.9 Specifically, a variety of drug-drug and drug-food
interactions can significantly impact the pharmacokinetics of warfarin and patients’ INR values.
In 1996, Rosendaal reported that extensive anticoagulation monitoring in specialized clinics
improves treatment effectiveness and reduces complications associated with warfarin therapy.10
Direct oral anticoagulants (DOAC):
In recent years, direct oral anticoagulants (DOACs) have been introduced into the US
market with the potential to overcome limitations of warfarin treatment. Dabigatran was the first
direct oral anticoagulation agent approved by the FDA in 2010, followed by rivaroxaban in 2011,
apixaban in 2013, and edoxaban in 2015. The DOACs, which are administered with a fixed dose
either once or twice daily, do not require the regular monitoring needed during warfarin
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treatment. In several clinical trials, these agents have demonstrated similar or superior efficacy
and safety compared to warfarin for the treatment of stroke prevention in AF patients.9-12
Use of Warfarin vs. DOAC:
Despite the favorable data on DOAC safety and efficacy, a number of barriers have
limited widespread utilization of the DOACs. While warfarin has a long history of clinical use,
little evidence currently exists surrounding the long-term safety and effectiveness of the DOACs.
Moreover, the four major clinical trials that assessed safety and efficacy of the DOACs
compared to warfarin took place under controlled conditions, and vulnerable populations like
elderly (aged ≥75 years) patients and those with severe renal or hepatic impairment were
underrepresented. Thus, these trials cannot determine conclusively that the overall safety and
efficacy of DOACs is the same in these higher risk populations as in their lower risk
counterparts.13 Given the lack of real world evidence on effectiveness and safety, some clinicians
still hesitate to prescribe DOACs in higher risk patient popluations.14 Additionally, unlike
warfarin, there is no antidote to reverse the anticoagulant effect of these agents in case of life
threating bleeding,. Although a new antidote agent for DOACs has been approved recently, still
there is a doubt about its effectiveness in reversing major bleeding events associated with
DOACs. Furthermore, the acquisition costs of the DOACs, which are still under patent
protection, are considerably higher than the cost of generically-available warfarin. Although
multiple studies have found that the DOACs can be cost-effective compared to warfarin in AF
patients, many of these studies reported that their results apply only when INR control with
warfarin treatment was poor.9,15 In other words, warfarin might be more economical in patients
with excellent INR control, as is commonly the case in patients treated at anticoagulant
clinics.10,12
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For these reasons, the majority of AF patients in the US are still treated with warfarin.13
According to a recent study by Desai et al., warfarin is the most commonly prescribed drug for
AF patients with CHADS2 scores ≥ 2.16 It is likely that warfarin will remain the most commonly
used anticoagulant in AF patients, especially among older adults, and switching to DOACs may
not be necessary for patients who are well maintained on warfarin.13
Medication Non-adherence:
Poor adherence to warfarin therapy is associated with increased risks of hospitalization
and mortality.2 These risks are especially high among the elderly population due to age-related
declines in mental and physical health.16 In the US, almost one-third of annual emergency
hospitalizations for adverse drug events have been attributed to warfarin, a finding that is even
more pronounced in older adult patients.17 These adverse drug events may be related to the
difficulty of warfarin dosing, the need for regular monitoring, and the many drug-drug and drugfood interactions that impact the drug’s pharmacodynamics. Proper adherence is essential to
maintaining a therapeutic INR, as even one missed dose can significantly impact the INR.
Despite the documented importance of warfarin adherence, nonadherence to the
medication is widespread. Kimmel et al. used the medication event monitoring system (MEMS)
to assess adherence to warfarin treatment and reported that up to 40% of patients were poorly
adherent.18 Another study by Davis et al., using the Morisky Medication Adherence Scale
(MMAS), found that adequate adherence was only reported in 50% of the participants, and it was
significantly associated with anticoagulation control.19 Based on the literature, patients with high
adherence to warfarin (PDC>80%) are associated with reduction in costs and resources
utilization compared to low adherent patients. It is estimated that well adherent patients are 28%
less likely to be hospitalized compared to poorly adherent patients.20
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The findings from the literature suggest that increased adherence to warfarin treatment in
the management of AF results in improved health outcomes.21 Despite these findings and an
array of interventions to improve warfarin adherence among AF patients, nonadherence
continues to be a significant problem in this population. Most of the existing interventions that
target poor adherence to warfarin are based on crude measures of medication adherence that
consider patients to have the same adherence patterns over time. Most adherence measures rely
on defined cut point, leading them to collapse a broad spectrum of adherence behavior patterns
into two groups, either adherent or non-adherent. Such a dichotomization can mask important
differences among patients’ adherence behavior, in turn having a great impact on the
effectiveness of the intervention. For example, the optimal intervention for a patient that is
highly adherent for short time and then discontinues the drug may differ from that of a patient
who is consistently non-adherent throughout their treatment period. In order to better tailor
interventions to improve warfarin adherence, there is a need for methods that can distinguish
between different patterns of warfarin adherence, as medication adherence is a dynamic behavior
that can change over time. In other words, there is a need for methods that not only measure
medication adherence but are also able to accurately predict the degree and timing of a given
patient’s non-adherence. Moreover, the ability to classify patients into groups according to their
adherence behavior over time may allow clinicians to develop targeted adherence interventions
for different groups.
According to the World Health Organization (WHO), medication adherence is defined as,
“the extent to which a person’s behavior – taking medications, following a diet, and/or executing
lifestyle changes - corresponds with agreed recommendations from a health care provider.”1 In
administrative claims data, medication adherence is most commonly measured using the
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proportion of days covered (PDC) or medication possession ratio (MPR).21-23 Both measures are
well-established and validated. However, in practice, these measures are frequently used to
dichotomously classify patients as adherent or not relative to predetermined threshold (e.g., PDC
> 80%). The use of the conventional adherence measures (e.g., PDC) can mask underlying
differences in medication refill behavior. For example, a patient with a PDC of 0.6 may have (1)
been highly adherent during the early follow-up but become increasingly less adherent as time
went on, (2) been poorly adherent during the early follow-up but become increasingly more
adherent over time, or (3) been intermittently adherent throughout follow-up period. All three
patients are considered non-adherent, but each may require a different type of intervention at
different times to improve their adherence behavior. Studies using these measures generally
assume that patients with similar scores maintained similar adherence patterns over the study
period and subsequently analyze those patients as a homogenous behavioral group. However,
underlying differences in the refill patterns and patients’ adherence behavior may play a crucial
role in the effectiveness of their medications and subsequently health outcomes and healthcare
utilization and associated costs.
Group Based Trajectory Model (GBTM):
Group-based trajectory models (GBTMs) are a new methodological approach that can
help to summarize long-term medication adherence by taking into account the dynamics of
medication adherence and changes in adherence behavior over time.21 GBTM is a latent class
analysis that provides an alternative method to capture adherence behavior over time.21 Unlike
PDC and other conventional adherence measures, GBTM is able to distinguish between different
patterns of medication non-adherence. The model provides a framework through which to
identify groups of individuals, termed trajectory groups, with similar behavioral patterns over a
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period of time.24,25 The GBTM is considered a person-centered approach, like cluster analysis,
that take into account the relationship among individuals.26 In GBTM, patients are grouped into
different trajectories based on their prescription refill patterns over time and summarized with an
average adherence in an easily interpretable graphical depiction. This approach allows patients to
be classified into different groups according to their adherence behavior over time, and the
characteristics of patients in each group can be identified and compared. By identifying key
characteristics associated with poor adherence trajectories, this can facilitate designing targeted
interventions more accurately.27 Moreover, GBTMs enable measurement of both the intensity
and the timing of medication adherence, thus capturing the dynamic nature of non-adherence
behavior in a way that conventional measures of adherence do not.
The GBTM has been widely used in sociological and medical research for understanding
disease progression and behavioral development patterns in children and adolescents.24,25 In
recent years, GBTMs have been applied to the study of medication adherence patterns and the
associations between adherence and health outcomes.21-23 Specifically, Franklin et al. used the
trajectory model to examine statin adherence, and Lo-Ciganic et al.22,23 applied GBTM to
classify diabetic medication adherence patterns and their association with clinical outcomes. In
both studies, the GBTM showed better predicative performance for clinical outcomes associated
with each trajectory group compared to conventional methods (e.g., PDC). Moreover, this
method has been shown to capture long-term medication adherence more accurately than
conventional measures.21
The application of GBTMs to the classification of medication adherence patterns offers
the potential to more comprehensively understand dynamic of adherence behavior and its
associated consequences. Furthermore, the use of GBTMs in clinical practice provides a method
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by which healthcare providers and payers can identify groups of patients, based on their refill
behavior, and tailored interventions to improve their adherence. By understanding predictive
characteristics of different adherence behaviors, this can better aid in customizing intervention
programs to the right patient at the right time. Tailored interventions can then be administered
with the most appropriate timing to better allocate resources and ultimately improve patient
outcomes and healthcare costs.
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1.2 Rationale
Atrial fibrillation (AF) is a growing health concern with significant complications that
affects large numbers of US patients, especially older adults.28 Warfarin is the most commonly
used drug for the prevention of stroke in AF patients in the US.29 Nearly two-thirds of AF
patients on Medicare have been prescribed warfarin.30 Due to the narrow therapeutic window of
warfarin and the severity of both treatment failure and overdosing, medication adherence is
critically important for patients on this anticoagulant. It is well established in the literature that
poor adherence to warfarin among AF patients is associated with poor health outcomes and
increased healthcare costs.31 However, medication nonadherence is a major barrier to effective
warfarin treatment and remains a significant problem despite numerous interventions to improve
adherence.
Given the prevalence and consequences of poor adherence to warfarin, there is a need to
better understand different patterns of adherence behavior and to more accurately identify
patients likely to be poorly adherent for tailored adherence interventions. No study yet has
assessed adherence to warfarin in AF patients by classifying patients according to their
adherence patterns over time. This study aims to classify patients according to their different
patterns of warfarin adherence over time and to identify predictors of adherence behavior.
Moreover, this study investigated the impact of each trajectory adherence pattern on subsequent
clinical outcomes and associated costs. Hence, this study is designed to enable healthcare
providers and payers to better identify patients with high risk of warfarin nonadherence and its
associated healthcare costs. Providers and payers will then be better equipped to implement
interventions tailored to a patient’s specific pattern of adherence. Furthermore, the results of this
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study can be used to assess the most effective interventions to improve warfarin adherence for
each trajectory group.

1.3 Specific Aims
The study aims to identify and describe warfarin adherence trajectory groups among AF patients
and to identify predictors associated with membership in each trajectory group. It also aims to
assess the impact of membership in each adherence trajectory group on clinical outcomes and
associated healthcare costs. The specific aims of the study are:
Specific Aim 1:
A. Identify and describe the trajectory groups of warfarin adherence in patients with AF in
Medicare population;
B. Estimate the likelihood of patients belonging to each adherence trajectory;
C. Identify patients’ characteristics and factors associated with each adherence trajectory.
Specific Aim 2:
A. Estimate the rates of hospitalizations related to a stroke or bleeding event (clinical
outcomes) associated with each adherence trajectory;
B. Evaluate the association between warfarin adherence trajectory group membership and
the likelihood of hospitalization due to a stroke or bleeding event.
Specific Aim 3:
A. Estimate the AF-related costs for each adherence trajectory group.

10

Chapter 2: Literature Review
2.1 Summary of literature on the use of GBTM in medication adherence
research
In order to describe the adherence trajectories of warfarin by using the Group Based
Trajectory Model (GBTM) and to assess the impact of adherence trajectory groups on clinical
outcomes and associated healthcare costs, we need to evaluate the literature relating to this topic.
This was done in two steps. First, we looked at studies that use GBTM in describing medication
adherence. Second, we evaluated studies that compared GBTM to PDC as an adherence measure.
A literature review conducted on October 2017 using PubMed/MEDLINE and CINAHL used
both Mesh terms and key words in appropriate combinations. The search terms were
combinations of: (group based trajectory modeling OR group based trajectory models OR group
based trajectory OR trajectory) AND (medication adherence OR "Medication
Adherence"[Mesh]), (group based trajectory modeling OR group based trajectory models OR
group based trajectory OR trajectory) AND (fill prescription), (group based trajectory modeling
OR group based trajectory models OR group based trajectory OR trajectory) AND (medication
compliance), (group based trajectory modeling OR group based trajectory models OR group
based trajectory OR trajectory) AND (medication persistence). (Table 1)
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Titles and abstracts from search result articles were screened using the following inclusion and
exclusion criteria:
Inclusion criteria:
1. Assess medication adherence
2. Apply Group Based Trajectory Model (GBTM)
3. Published in English
Exclusion criteria:
1. Apply GBTM to describe trajectories of disease progression
2. Review paper, report, or proposal.
The search on PubMed and CINAHL revealed a total of 208 articles. After eliminating
duplicates and applying inclusion and exclusion criteria, 23 research articles remained. Out of
these 23 articles, 19 articles were chosen to be discussed as they assessed medication adherence
specifically by performing GBTM. The four excluded studies used GBTM to describe patterns of
disease progression or program intervention (Figure 1). The references of the selected studies
were reviewed to identify additional studies that meet inclusion criteria. One additional study
from the references was added to the literature review.
The total search resulted in 20 study articles that reported on the use of GBTM in
describing medication adherence.
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Table 1: Search term combinations used and resulting number of articles
Search term combinations

Total

Articles

number of

Meeting

articles

Inclusion
Criteria

((group based trajectory modeling) OR (group based trajectory

72

22

9

3

69

20

58

21

models) OR (group based trajectory) OR (trajectory)) AND
(("Medication Adherence"[Mesh]) OR medication adherence)
((group based trajectory modeling) OR (group based trajectory
models) OR (group based trajectory) OR (trajectory)) AND fill
prescription
((group based trajectory modeling) OR (group based trajectory
models) OR (group based trajectory) OR (trajectory)) AND
medication compliance
((group based trajectory modeling) OR (group based trajectory
models) OR (group based trajectory) OR (trajectory)) AND
medication persistence
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Total search results (n=208 articles)

Titles and abstracts reviewed for eligibility

Excluded (n= 185)
duplicate or not met
inclusion/ exclusion
criteria

Articles reviewed for eligibility (n=23)

Excluded (n= 4) did not
use GBTM to describe
medication adherence

Articles included (n=19 articles)

Included (n= 1) from
references of the selected
studies

Total articles included (n=20 articles)
Figure 1: Selection process flow chart
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Overall the search revealed a total of 20 relevant studies that applied GBTM to describe
medication adherence patterns among different disease conditions and drug classes. All the
identified papers were recently published (2010-2017). Six studies were conducted outside the
United States (one in Taiwan, and five in Europe).32-37 Study populations vary throughout the
literature, as some studies examined only pediatrics patients,38-40 others included all adult
patients ≥ 18 years old, and some studies assessed adherence specifically for the elderly
population. The selected studies assess medication adherence in different disease conditions,
however, the majority of them focused on populations with cardiovascular
diseases.22,23,32,33,35,37,41-44 (Table 2)
Important criteria in comparing studies
There are several important criteria to consider when comparing between different studies
that applied GBTM. These are the time period of the study, the number of trajectory groups
resulting from the analysis, the types of trajectory groups identified, and the drug classes studied.
Time period of the study. First is the time of the outcome’s measuring period, as it can
influence the shape of the group trajectories. The time period to measure medication adherence
varied across studies. Some captured adherence for a short period only (e.g., four months) while
others extended over longer periods of time (e.g., six years).
Number of trajectory groups. Another important criterion to consider when comparing
between the different trajectory models is the number of groups that resulted from the GBTM.
The number of trajectory groups describes the level of diversity in the outcome’s patterns (e.g.
medication adherence patterns). As the number of groups increases, the model can better explain
the heterogeneity in the outcome trajectories among the study population. On the other hand, a
large number of groups can be difficult to interpret, so there is always a tradeoff between the
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accuracy of capturing the underlying reality and the ease of interpreting the analysis. Throughout
the literature, the number of trajectory groups identified varied between the studies. Overall, the
optimum number of groups identified in most of the studies was four to six adherence groups.
However, a study by Lo-Ciganic et al., for hypoglycemic drugs was able to classify patients’
adherence patterns using seven trajectory groups.23 At the other extreme, Greenley et al., found
only two adherence trajectories for patients on thiopurine for Inflammatory Bowel Disease
(IBD).40 The identification of only two adherence groups may have been due to a small sample
size (n= 96) which limited the ability to add more groups because group sizes were too small (i.e.
the proportion of patients in each group should not be less than 5% of total sample).
Types of trajectory groups. The third criterion to consider when comparing between
GBTMs across the literature relates to the types of the identified trajectory groups. The most
common trajectory groups identified in the literature were: “perfect adherence”, “nonadherence”, and “slow-decline adherence”. The perfect adherent group was described as a steady
line plotted on a graph over time, where the patients belonging to this group have a persistently
good adherence level to their medication over the study period. The average PDC value for the
patients in this group is usually >90 %. Consistently throughout the literature, the highest
proportion of patients falls in the “perfect adherence” trajectory. On the other hand, the “nonadherent” group was described in most of the studies as constant low or non-adherence over the
study period, with less than two prescriptions filled, and can be described in a graph as a low
steady line. Some of the studies reported that it was hard to distinguish whether the patients who
belong to this group were truly non-adherent or just discontinued their medication and switched
to another class.23 The final commonly identified group was the trajectory in which patients

16

started with good adherence and became slowly non-adherent over time. The average PDC for
this group was 50-60%.
Studies differed when describing the trajectory groups between perfect adherence and nonadherence groups. Few studies identified trajectory groups in which patients experienced a very
rapid decline in their adherence pattern.34,38,41,45-47 In these studies, they included new patients
who filled at least one prescription of medication. So, a trajectory of very rapid decline can be
related to the improvement in the disease condition to the point that patients do not require
treatment any more, or that patients were on a one-time dose and then discontinue treatment.
This is can be In contrast, a study by MacEwan identified trajectory where the adherence was
good at first and then declined after a period of time (e.g. after 6 months or 9 months).48 These
differences in the identified trajectory groups among the studies can be due to several factors
related to study population, disease characteristics, sample size, and the assigned duration for
assessing medication adherence (study period). All of these factors can play a role in describing
adherence trajectory patterns.
Drug classes studied. Most GBTM studies on patterns of medication adherence limited
their analysis to a single therapeutic drug class over time which limited the ability to identify
differences across medications in a single population. An exception was a study by Librero et al.
that examined and compared adherence trajectories for four different drug classes: beta-blockers,
ACEIs/ARBs, antiplatelet agents, and statins for discharged patients with congestive heart failure
(CHF).33 The GBTM showed three different patterns of trajectory for this population that varied
depending on the drug class. There were five trajectories for the antiplatelet cohort, four
trajectories for the beta-blocker and ACEI/ARB cohort, and three trajectories for patients on
statins indicating that adherence trajectories were not homogeneous for CHF discharge patients
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prescribed different medications. The authors concluded that the GBTM approach better captures
the dynamic nature of the adherence behavior over time than other traditional measures (e.g.,
PDC).
Patient Characteristics Associated with Trajectories
The literature suggests that a deeper understanding of patients’ characteristics associated
with each trajectory group can help in identifying patients in poor adherent groups and in
implementing more effective interventions to improve their adherence. Adherence groups may
vary upon demographic characteristics and benefit differently from alternative intervention
strategies. In addition, adherence trajectories may diverge based upon patients’
characteristics.33,48
Different studies in the literature identified characteristics associated with poor and
intermediate adherence trajectories which can serve as a signal for the clinicians to target those
patients with a suitable intervention at the proper time. For example, Juarez et al., found that the
white, Asian, and Pacific Islanders patients with CHF were more likely to have low adherence in
the first year after discharge compared to black patients.42 Such findings can aid in the targeting
of patients with the right intervention at the early phase after discharge to ensure better
adherence behavior. Thus, a useful application of the GBTM rests on its ability to identify
patients with a high probability of having a poor adherence trajectory and thereby targeting them
with proper intervention.33
Some studies examined the association between patients’ demographic and clinical
characteristics with different adherence trajectories. Age, gender, race, and educational level
have been found to be associated significantly with adherence trajectories.23,34-36,42,43,49 It has
been reported that the patients in the lower adherent groups tend to be younger, non-white, males
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with low educational level. Higher adherent trajectories are more common in older, white
populations with higher educational level (bachelor’s degree and above). Other studies have not
found an association between these demographics factors and adherence trajectories.39 This may
be due to the different characteristics of the study design including: disease population, study’s
sample size, and study period.
Other population characteristics have been related to adherence trajectories. Low
socioeconomic status is associated with lower adherent trajectories.32,34,39,48 Higher copayment
share is also associated with lower adherent trajectory groups.33 The presence of comorbidities
has been found to be a strong predictor of low adherence groups.48,50 Many of these
characteristics are also variables described in theoretical frameworks related to medication
adherence, such as the Andersen Behavioral Model (ABM).51
Trajectories and Healthcare Utilization
Adherence trajectories have been associated with healthcare utilization. Six studies
examined specifically at the impact of adherence trajectories on healthcare events (e.g.,
hospitalization events, ED visit, disease-related adverse events, or death).22,23,38,48,52,53 They
found that better adherent trajectories were associated with fewer hospitalization events and a
lower mortality rate. Mac Ewan et al., used GBTM to stratify schizophrenic patients treated with
oral Atypical Antipsychotics into groups based on their adherence behaviors.48 They reported
that patients in the perfect adherent group had fewer ED visits compared to low adherent groups.
Lo-Ciganic et al., assessed the association between trajectories of hypoglycemic medication
adherence and risk of ED visit and hospitalization.23 They concluded that low and moderate
adherent and non-adherent group membership was associated with higher risk of ED visits/
hospitalizations in contrast to perfect-adherent trajectory. A study by Winn et al., examined the
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relationship between adherence trajectories of endocrine therapy and death in women with breast
cancer.53 They found that patients in rapidly and moderate decline adherence trajectories had
significantly higher risk of death compared to perfect adherent trajectories. Furthermore,
Franklin et al., studied the association between trajectories of statin adherence and cardiovascular
events, and they concluded that lower adherent groups were associated with higher risk of
cardiovascular events compared to perfect adherent trajectories.22 A study by Modi et al.,
evaluated the relationship between adherence trajectories of antiepileptic drugs in a pediatric
population with seizure outcomes, and they reported that patients with unstable adherence levels
have a higher rate of seizures.38 Similarly, a study by Gueorguieva et al., assessed the
relationship between adherence trajectories of pharmacological treatment (naltrexone,
acamprosate), behavioral interventions, and drinking outcomes and concluded that the perfectadherent group experienced less drinking compared to non-adherent groups.52
Predictive Validity of GBTM
Several published studies in the literature have examined the predictive performance of
GBTM compared to conventional measures (e.g. PDC). Six out of seven studies showed GBTM
to be superior in capturing longitudinal adherence patterns than PDC.22,23,32,44,50,53 A study by
Hargrove et al., compared adherence trajectories identified by GBTM to conventional adherence
measures (proportion days covered (PDC), medication possession ratio (MPR) and reported that
a six group trajectory model better distinguished between adherent and non-adherent months
than the PDC or PMC, especially for patients with inconsistent adherence patterns.44 A study by
Aarnio et al., examined the relationship between socioeconomic position (SEP) and statin
adherence for men compared to women using GBTM and conventional measures (PDC<80%).32
They found that GBTM provided a better description of adherence behavior and more
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comprehensive details in differentiating between adherence groups. Winn et al., investigated the
association between endocrine therapy adherence trajectories and mortality compared to the
conventional PDC measure.53 They found that both measures show significant association
between adherence and mortality; however, the hazard of survival when using PDC was very
small (hazard ratio (HR) 1.21) and did not distinguish between different adherence groups as
seen when using GBTM. Lo Ciganic et al., examined the impact of adherence trajectories in
predicting diabetes-related hospitalization and ED visits compared to conventional PDC
measures.23 They concluded that the adherence trajectories in the multi-variants model showed
better prediction for the clinical outcomes compared to a dichotomous PDC measure. Similarly,
Franklin et al., reported that the use of statin adherence trajectories predicts cardiovascular
events better than the traditional PDC ≥ 80% threshold.22 Finally, Li et al., compared biological
treatment adherence patterns using GBTM and PDC in patients with psoriasis.50 The GBTM
identified four trajectory patterns. In order to compare the two measures, an equivalent number
of groups were constructed from the same cohort of patients using the PDC measures in the
following way: Group 4 (PDC≥ 75%), Group 3(50% <PDC <75%), Group 2 (25%< PDC<
50%), and Group 1 (PDC ≤25%). The authors reported that GBTM and PDCs were similar in
categorizing patients in the extreme groups (perfect-adherent and non-adherent groups).
However, for the patients in the intermediate groups, there was a difference in the longitudinal
adherence patterns when using GBTM compared to PDC. The use of GBTM resulted in a better
classification of adherence patterns compared to the traditional PDC measure.
Only one study has reported that GBTM might not accurately reflect adherence behavior.37
In this study, the authors evaluated the predictive validity of GBTM in patients with
hypertension. They identified four trajectories for hypertensive medication adherence for 905
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patients. The predictive validity was measured by assessing relationships between trajectory
groups and blood pressure (BP) measurements. They did not find association between adherence
trajectories and BP measurements, although they offered several explanations for their results.
First, the result could be related to the “white coat adherence effect”, in which patients exhibit
better adherence behavior in the day prior to the clinic visit. The theory posits that since patients
already knew that they would undergo a BP measurement during their visit, they adhered to their
medication before the visit. Second, blood pressure was only measured a single time, which
might make it less reliable. Third, the small sample size restricted the generalizability of the
study results.
Summary of Findings
Based on this literature review, there are important points to consider when applying GBTM.
GBTM assumes that there are an infinite number of patterns that can model differences between
the individuals in the real world.54 Therefore, when starting to build a GBTM, there are an
almost unlimited numbers of possible trajectory groups to describe the different adherence
patterns seen with the real-world patients.33
Depending on the criteria used for fitting the final model, the number of trajectory groups is
identified using the following methods: 1) model fit using Bayesian information criteria (BIC),
where a lower value indicates better fit; 2) the proportion of patients in each group is not less
than 5% of total sample; and 3) Nagin’s criteria for model adequacy.33 Then, after identifying the
appropriate number of trajectory groups, the patients in the cohort are classified into these groups
based on their membership probabilities (that is, group membership is determined by the highest
likelihood of belonging to a certain trajectory group). Once classified, the GBTM assumes that
patients in groups will have similar patterns of adherence over time.
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The literature appears to show that trajectory group classification is most beneficial for
patients who are somewhere between perfect adherence and non-adherence. GBTM is no better
than PDC measures for these patients. The value of GBTM lies in understanding adherence
patterns in intermediate groups (e.g., slowly declining and low adherence then rapid increase
groups). PDC measures lump patients into single groups while GBTM identifies more adherence
patterns. For instance, a study by Mardby et al., found PDC classified half of the study
population as non-adherent.34 In contrast, GBTM found one third of the study population nonadherent within the first few months after initiating the therapy because it differentiated nonadherence according to the time it occurred. The ability to more finely differentiate patient
adherence over time is why the GBTM has the advantage over PDC measurement.
It is important to understand that the main goal of GBTM is to describe and summarize
different patterns, and to simplify the complexity of the real-world situation in order to better
understand differences between patients’ behaviors.54 Thus, the summarization of the real-world
differences means that there must be some approximation for the simplicity of understanding and
interpretations. The key point is that the individuals belonging to each trajectory group are not
identical, rather similar in many aspects.
GBTM is an innovative approach that can be used to describe adherence patterns by taking
into account the dynamics of medication adherence and changes in adherence behavior over
time. GBTM can be clinically useful for healthcare providers and payers in tailoring adherence
interventions to better allocate resources and enhance patients’ outcomes and overall healthcare
costs.
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Table 2: Summary of identified studies
Authors

Objective

Population

Type of
treatment

1. Dillon et al.,
201737

1.Characterize
adherence to
antihypertensive
medication
2. Test predictive
validity of GBTM
against blood pressure
measurement
1.Use GBTM to
identify
antihypertensive
adherence trajectories
2.Comapre adherence
trajectories to
traditional adherence
measures
3. Identify patients
characteristics
associated with
adherence trajectories
1. Identify adherence
trajectory for oral
atypical antipsychotics
(OAA)
2. Identify associated
factors

Patients aged
≥ 65 years old

Antihypertensive

Length of
study
period
1-year

Medicare
patients aged
≥ 65 years old

Antihypertensive

1-year

US

Adult
schizophrenia
patients

Oral atypical
antipsychotic

1-year

1. Identify adherence
trajectory of statin
2. Examine
association between
SEP and adherence
trajectories

Patients aged
45 to 75 years

Statin

18-months

2. Hargrove et
al., 201744

3.MacEwan et
al., 201648

4.Aarnio et
al.,201632

Country

Sample
size

Republic
of
Ireland

905

Trajectory group

Clinical outcomes

Conclusion

1.Perfect adherence
2.High adherence
3.Moderate non-adherence

-

GBTM identified 3
trajectories.
However, did not
show predictive
validity with BP
measurement

282,520

1.Perfect adherence
2. Rapid decline, then increase
3. Moderate decline, then
increase
4. Moderate decline
5. Rapid decline
6. Very rapid decline

-

GBTM is an
effective method to
identify patterns of
medication
adherence compared
to PDC

US

29,607

1. Perfect adherence
2. Decline after 3 months
3. Decline after 6 months
4. Decline after 9 months
5. Rapid decline, then increase
after 6 months
6. Very rapid decline

Psychiatric inpatient
admission and ED
visit

-Adherence patterns
identified by GBTM
are more varied than
research based on
PDC
-Lower adherence
trajectories
associated with
higher ED visits

Finland

116,846

1. Perfect adherence
2. High adherence
3. Rapid decline, then increase
4. Moderate decline
5. Rapid decline
6. Very rapid decline

-

SEP is associated
with low adherence
groups. Overall,
GBTM provide
insight to dynamics
of adherence
behavior
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Table 2: Continued
Authors

Objective

Population

Type of
treatment

Length of
the study
period
9-months

Country

Sample
size

Spain

7,462

Trajectory group

Clinical outcomes

Conclusion

1.Perfect adherence
2. Low adherence, then
increase
3. Moderate decline, then
increase
4. Moderate decline
5. Rapid decline

-

GBTM identified
distinct adherence
trajectories for
difference preventive
medication for CHD.
It showed advantage
over traditional
measure
- GBTM identified 5
distinct patterns
-low adherence
trajectories
associated with lower
SEP
Lower adherence
trajectories
associated with
higher
ED/hospitalization
events

5.Libero et al.,
201633

1. Identify adherence
trajectory for ACEI,
statin BB, and
antiplatelet
2. Identify associated
factors

Patients
discharged
with coronary
heart disease
(CHD)

ACEI, statin BB,
and antiplatelet

6.Mårdby et
al., 201634

1. Identify adherence
trajectory of
antidepressants
2. Identify associated
factors

Patients aged
18–85 years

Citalopram

24-months

Sweden

54,248

1. Perfect adherence
2. Moderate decline
3. Rapid decline, then increase
4. Rapid decline
5. Very rapid decline

-

7. Lo-Ciganic
et al., 201623

1. Identify adherence
trajectory of oral
hypoglycemic
2. Identify associated
factors
3. Examine association
with clinical events
1. Identify adherence
trajectory of ET
2. Identify associated
factors
3. Examine association
with mortality
1. Identify adherence
trajectory of
hypoglycemic
2. Identify associated
factors

Patients aged
18–64 years
with diabetes
(DM)

Oral
hypoglycemic
medication

1-year

US

16,256

1. DM related ED
visit/hospitalization
2. All cause ED
visit/hospitalization

Women with
breast cancer

Endocrine
therapy (ET)

1-year

US

9,492

1. Perfect adherence
2. High adherence
3. Moderate decline
4. Moderate non-adherence
5. Rapid decline, then increase
6. Rapid decline
7. Very rapid decline
1. Perfect adherence
2. Slow decline
3. Rapid decline, then increase
4. Moderate decline
5. Rapid decline

Patients aged
≥ 18 years
type 2
diabetes

Oral
hypoglycemic
medication

Six-years

Taiwan

12,123

8. Winn et al.,
201653

9. Chen et al.,
201635
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1. Perfect adherence
2. Moderate adherence, then
increase
3. Moderate decline
4. Low adherence, then
increase

Mortality

Low adherence
groups associated
with higher mortality
rate

-

GBTM help in
identifying
heterogeneity of
medication adherence

Table 2: Continued
Authors

Objective

Population

Type of treatment

Length of
the study
period
1-year

Country

Sample
size

US

77,703

10. Franklin et
al., 201541

Identify adherence
trajectory of statin

Patients aged
≥ 65 years old

Statin

11.Newmancasey et al.,
201549

1. Identify
adherence trajectory
of glaucoma
medication
2. Identify
associated factors
1. Identify
adherence trajectory
of ACEI
2. Identify
associated factors

Patients ≥40
years old
treated for
glaucoma

Glaucoma
medication

4-years

US

1,234

Patients with
Congestive
Heart failure
(CHF)

ACEI

1-year

US

10,986

1. Identify
adherence trajectory
of statin
2. Examine
association with
clinical events

Patients in the
UnitedHealth
Optum
Research
Datamart,
aged 35-64
years

Statin

1-year

US

519,842

12.Juarez et al.,
201542

13. Franklin et
al., 201522
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Trajectory group

Clinical outcomes

1.Perfect adherence
2. Moderate adherence
3. Rapid decline, then increase
4. Moderate decline, then
increase
5. Rapid decline
6. Very rapid decline
1. Perfect adherence
2. Moderate non-adherence 3.
Moderate decline
4. Low adherence, then
increase
5. Rapid decline
1.Perfect adherence
2. Moderate decline
3. Low adherence, then
increase
4. Rapid decline

-

Initial adherence
behavior associated
with better future
adherence

-

Adherence patterns
for first year, had
great impact on
future adherence
behavior

-

Patients factors
associated with low
adherence trajectories
can be used to target
interventions

1.Perfect adherence
2. Rapid decline then increase
3. Moderate decline
4. Moderate decline, then
increase
5. Rapid decline
6. Very rapid decline

Hospitalization for
an acute coronary
event,
revascularization,
cerebrovascular
event, or heart
failure

Conclusion

Adherence
trajectories predicts
future clinical
outcomes better than
PDC

Table 2: Continued
Authors

Objective

Population

Type of
medication

14. Li et al.,
201450

1. compares GBTM
and PDC
2. identify the clinical
and demographic
factors associated
with adherence
groups

Patients >18
years old with
Psoriasis

15. Modi AC et
al., 201438

1.Identify adherence
trajectory of
antiepileptic drugs
2.Examine
association with
seizure outcomes

Children
diagnosed
with epilepsy

Treated with
at least one
biologic:
etanercept,
adalimumab,
ustekinumab,
and
infliximab
Antiepileptic
drugs

16. Greenley et
al., 201440

1. Identify adherence
trajectory of
thiopurine
2. Identify associated
factors
1. Identify adherence
trajectory of statin
2. Identify associated
factors

Adolescents
with
Inflammatory
Bowel Disease
(IBD)
Patients
initiating
statin in CVS
Caremark

17.Franklin et
al., 201343

Length of
the study
period
1-year

Country
US

3,249

1.Perfect adherence
2.Moderate non-adherence
3.Moderate decline
4.Rapid decline

2-years

US

109

1. Perfect adherence
2. Slow decline
3. Rapid decline, then
increase
4. Very rapid decline

Thiopurine

6-months

US

96

1. Perfect adherence
2. Moderate non-adherence

-

Nearly 60% of
participants are
perfectly adherent

Statin

15-months

US

264,789

1. Perfect adherence
2. Rapid decline then
increase
3. Moderate decline
4. Moderate non-adherence
5. Rapid decline
6. Very rapid decline

-

GBTM summarized
adherence patterns
better than traditional
measures
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Sample size

Trajectory group

Clinical outcomes
-

Seizure outcomes

Conclusion
GBTM is better in
capturing dynamic of
adherence behavior
than PDC

Low adherence
trajectory associated
with higher seizures

Table 2: Continued
Authors

18.Gueorguieva
et al., 201352

19. Modi AC et
al., 201139

20. Glass
et al., 201036

Objective

Population

Type of
treatment

Length of
the study
period
4-months

Country

US

Sample size

Trajectory group

Clinical outcomes

Conclusion

1,174

1. Perfect adherence
2. Moderate non-adherence 3.
Rapid decline

Percent days
abstinent (PDA) and
percent heavy
drinking days
(PHDD)

Lower adherence
trajectories associated
with worse drinking
outcomes

GBTM identified 5
patterns for
antiepileptic
medication adherence,
and were significantly
associated with SEP
Substance and alcohol
consumption,
psychiatric treatment,
and loss of social
support were
significantly
associated with lower
adherence trajectories

1. Identify adherence
trajectory of
medication adherence
and participation in
Combined Behavioral
Intervention
2.Estimate effects of
adherence trajectories
on drinking outcomes
1. Identify adherence
trajectory of
antiepileptic drugs
2. Identify associated
factors

Abstinent
alcohol
dependent
patients
enrolled in
COMBINE
study

Naltrexone,
Acamprosate

Children
diagnosed
with epilepsy

Antiepileptic
drugs

6-months

US

124 patients

1. Perfect adherence
2. slow decline
3. Moderate non-adherence
4. Moderate decline
5. Rapid decline

-

1. Identify adherence
trajectory of
combination
antiretroviral therapy
(cART)
2.Identify associated
factors

HIV adult
patients

Combination
antiretroviral
therapy
(cART)

6-years

Switzerlan
d

6,709
patients

1. Moderate non-adherence
2. Moderate decline
3 Low adherence, then
increase
4. Low adherence

-
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2.2 Gaps in the literature
This literature review found that GBTM is considered a better approach to capture
longitudinal patterns of medication adherence compared to conventional measures. Moreover,
the literature indicates that GBTM can provide more details on characteristics of patients who are
likely to be non-adherent. Based on published results, the GBTM approach can better predict
clinical outcomes compared to conventional measures.
No study has yet applied GBTM to capture long-term adherence trajectories of warfarin in
AF patients. Moreover, no published study has used GBTM to describe key characteristics of
different patterns of warfarin adherence. This study is the first to describe warfarin adherence
patterns using GBTM and to assess relationships between adherence trajectories, hospitalization,
and healthcare-related costs. The results of this study can help in identifying AF patients who are
more likely to be non-adherent to warfarin therapy and to have higher healthcare utilization,
allowing healthcare professionals to target them with suitable interventions.
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2.3 Conceptual framework
In this study, the Andersen Behavioral Model (ABM) was used to evaluate the relationship
between medication adherence and health outcomes. This model is useful in identifying factors
related to warfarin adherence and explaining the association between adherence and health
outcomes. The model was first developed to better predict utilization of health services and
behaviors and has since been adapted to better understand medication adherence.51,55,56 The
ABM classifies the predictors of health behavior into 3 main components: predisposing factors,
enabling factors, and need factors. The predisposing factors are those factors that explain an
individual’s tendency toward certain behavior and include demographic, social structure, and
health belief variables. Enabling factors are the individual resources that promote or inhibit
certain behaviors, including personal and community factors. Need factors relate to an
individual’s assessment of their need to adopt a health behavior and include perceived factors
(e.g. perception of illness) and evaluated factors (e.g. illness severity). In the ABM, these three
components affect health behavior which, in turn, impacts health outcomes. Moreover, in this
model, the health outcomes also have an impact on the predisposing, enabling, and need factors
as well as overall health behavior.
In this study, the ABM has been modified to fit medication adherence in older populations
based on the published literature (Appendix A).51,55 The predisposing factors in the adherencespecific ABM model include demographic characteristics (age, gender, and race), in addition to a
social factor, educational level. Furthermore, two additional factors have been added to the
original model: treatment characteristics (dosing, regimen complexity, INR monitoring) and
disease characteristics (cognitive impairment and depression). These two factors were added as
they have been found to significantly impact medication adherence behavior in older adults.51,57
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The enabling factors in this model include personal-level factors, namely, insurance status and
income, as well as a community-level factor, specifically, social support. The need factors are
comorbidity, illness severity, and AF-specific symptoms. Additionally, anticoagulant clinic
participation has been added to the original model given its importance in explaining warfarin
adherence behavior. Each of these factors has previously been identified as a significant
predictor for warfarin adherence in older adults.57
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Chapter 3: Method
This chapter explains the methodology used to address specific aims 1, 2, and 3. It describes data
sources, study design, study population, variables, outcomes measures, and statistical analyses.
Approvals
The proposal for this study was approved by the Virginia Commonwealth University institutional
review board (IRB) under expedited review. In addition, the study was also approved by the
Centers for Medicare and Medicaid Services (CMS).
Data Source:
The data employed for this study was obtained from the CMS. The study used 2008-2010
Chronic Condition Data Warehouse (CCW) Medicare files, which was provided via the Research
Data Assistance Center (ResDAC). Medicare is a federal insurance program that is offered for
people aged 65 years or older, end stage renal disease patients, and patients with disabilities.
The population of interest for this study was AF patients treated with warfarin. The majority
of AF patients in the database are ≥65 years of age. According to the CCW sample size
estimator, five percent of all the Medicare beneficiaries were diagnosed with AF, and almost two
third of AF patients were being treated with warfarin.58 Medicare data were used in this study as
this resource is considered a good source for information on the elderly population. Moreover,
claims data are known to be associated with lower recall bias and self-reporting bias compared to
survey data.
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In this study, a 5% random sample of all Medicare beneficiaries in 2008 to 2010 was used to
provide information on health services and associated billings issued under Medicare Part A
(inpatient), Medicare Part B (physician visits, outpatient care, ED visits) and Medicare Part D
(pharmacy drug claims). A number of different Medicare files were employed to address the
objectives of this study. The beneficiaries’ information linked across files using a unique coded
patient identifier to prevent patient identification (BENE_ID). The Master Beneficiary Summary
file (MBSF) was used to obtain patients’ demographic and enrollment information. The MBSF
Chronic Condition and Other Chronic Condition files were used to identify different AF patients
and different comorbid conditions. The beneficiary was flagged with a specific condition in the
Chronic Condition and Other Chronic Condition files based on the existence of one inpatient or
at least two outpatient claims. Files of Part A contain all claims related to hospital services and
inpatient services and was used to identified all hospitalization events related to AF and to
calculate associated costs. Files from Medicare Part B contain all hospital outpatient and
anticoagulant clinic claims. Medicare Part D events file (PDE) and drug characteristics file
contain information regarding prescription drug claims, including national drug code (NDC),
date of prescription refill, quantity supply, days of supply. These claims were used to identify
patients who are treated with warfarin and to assess adherence trajectories. The files and the
variables that have been used are shown in the tables below.
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Table 3: Master Beneficiary Summary File (MBSF)
SAS Variable Name

Description

BENE_ID

An unique encrypted beneficiary identification number that was
used to link the beneficiaries across files

AGE

Beneficiary’s age at the end of the year

SEX

Beneficiary’s gender

RACE

Beneficiary’s race was categorized as White, Black and Others

DEATH_DT

Beneficiary’s date of death was used to identify patients who were
alive from baseline through the measurement period

A_MO_CNT

Month counts of part A coverage, used to identify beneficiaries
with continuous enrollment in part A

B_MO_CNT

Month counts of part B coverage, used to identify beneficiaries
with continuous enrollment in part B

PTD_MO

Month counts of part D coverage, used to identify beneficiaries
with continuous enrollment in part D

HMO_MO

Total number of months of HMO coverage, used to identify
beneficiaries with fee-for–service versus HMO coverage

PTD_CNTRCT_ID (112)

A unique encrypted contract ID, used to identify patients with
stand-alone prescription (i.e. no MA-PD beneficiary)

CST_SHR_GRP_CD(112)

Cost share group code, used to identify beneficiaries with low
income subsidy as proxy for income variable
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Table 4: Inpatient and outpatient files
SAS variable Name

Description

BENE_ID

An unique encrypted beneficiary identification number that was
used to link the beneficiaries across files

CLM_ID

Unique encrypted identifier number for claims used to identify
duplication of claims

CLM_THRU_DT

Claim date

PMT_AMT

Amount of payment made from the Medicare for the services
covered by claim

UTIL_DAY

Number of days utilized by claims, used in calculating amount
paid by Medicare not included in the claim payment amount

PER_DIEM

Pass through amount not included in the claim payment amount

PRPAYAMT

Amount paid by primary payer other than Medicare

DED_AMT

Beneficiary deductible amount for inpatient service

COIN_AMT

Beneficiary coinsurance amount for inpatient service

BLDDEDAMT

Beneficiary blood deductible liability amount

ADMTG_DGNS_CD

Beneficiary's initial diagnosis at admission ICD-9-CM code

PRNCPAL_DGNS_CD

Primary diagnosis ICD-9-CM code

ICD_DGNS_CD1-25

Claim diagnosis code

ADMSN_DT

Claim admission date

HCPCS_CD

The Health Care Common Procedure Coding System (HCPCS)
is used to identify anticoagulant services

CLM_LINE_NUM

Claim line number, used to identify line outpatient claims
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Table 5: Part D Event (PDE) File
SAS variable Name

Description

BENE_ID

An unique encrypted beneficiary identification number that was used to
link the beneficiaries across files

PDE_ID

An unique encrypted Part D identification claim number used to
identify duplicate claims

SRVC_DT

Prescription service date

BENEFIT_PHASE

Benefit phase of the part D event, used to identify beneficiary in the
coverage gap

PTPAYAMT

Amount paid by patient for claim

CPP_

Amount paid by Medicare for claim

GNN / PRDSRVID

Product service ID by NDC

DAYSSPLY

Number of days' supply of the drug, used to measure warfarin
adherence
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Table 6: MBSF Chronic Condition and Other Chronic Condition Files
SAS variable Name

Description

BENE_ID

An unique encrypted beneficiary identification number that was
used to link the beneficiaries across files

AMI

Acute Myocardial infarction

ALZ

Alzheimer’s disease

ATRIAL_FIB

Atrial Fibrillation

COPD

Chronic Obstructive Pulmonary Disease

CHF

Congestive Heart Failure

DIABETES

Diabetes

RA_OA

Rheumatoid Arthritis

STRKETIA

Stroke /Transient Ischemic Attack (TIA)

CNCRBRST

Breast Cancer

CNCRCLRC

Colorectal Cancer

CNCRPRST

Prostate Cancer

CNCRLUNG

Lung Cancer

CNCRENDM

Endometrial Cancer

DEPRESSN

Depression

HYPERT

Hypertension

HIVAIDS_MEDICARE HIV/AIDS
BIPL_MEDICARE

Bipolar disorder

LIVER_MEDICARE

Liver Disease/Cirrhosis and other liver conditions exclude
Hepatitis

SCHIOT_MEDICARE

Schizophrenia and other psychotic disorders

PVD_MEIDCARE

Peripheral Vascular Disease

37

Study design:
This is a retrospective cohort study examining the adherence behaviors and healthcare
utilization of AF patients treated with warfarin using Medicare claims data from 2008 to 2010.
The index period defined for the study was July 1, 2008 – December 31, 2009 and the date of the
first warfarin prescription claim received in the index period was assigned as the index date for
warfarin users. A pre-index period was defined as the six months period prior to the index date.
A pre-index period is important to identify baseline characteristics and incident warfarin users.
The incident users were defined as those patients who did not have a prescription claim for
warfarin in the six months prior to the index date. Patient prescription refill claims were followed
for 12 months from the index date to assess warfarin adherence. Any additional period after the
12-month follow-up period was used to measure AF-related clinical outcomes (AF-related
hospitalizations) and to calculate AF-associated costs (Figure 2).

First 6 months used
to identify first
warfarin
prescription

Pre-index period
(6 months not using
anticoagulants)

Index period
(18 months identify warfarin
prescription and measure adherence)

Figure 2: Study timeline
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Post index period (identify
first hospitalization)

Population and setting:
From the Medicare 5% sample population, all patients ≥ 65 years old with Atrial
Fibrillation (AF) and treated with warfarin between July 1, 2008 and December 31, 2010 were
eligible for inclusion in this study. Patients with AF were identified using the International
Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) codes from
principle diagnosis, admitting diagnosis or any of the 25 ICD diagnosis variables in the inpatient
(Part A), outpatient (Part B) claims, or the chronic condition file. Any patient who had at least
one inpatient claim or two outpatient claims for AF in any of the claim fields was included in the
study (ICD-9-CM codes 427.31 is associated with AF). The National Drug Codes (NDC) of
warfarin were used to identify patients on warfarin treatment. Any AF patient who had at least
two warfarin prescription claims from July 1st 2008 to December 31, 2009 in the claims data was
included in the study. A minimum of two claims of warfarin was chosen to exclude patients who
might be given one prescription of warfarin and then discontinued treatment.
Only the beneficiaries with fee-for-service benefits and continuous enrollment in the
Medicare Parts A, B and D throughout the study period were included in the study. The
continuous enrollment was defined as having 12 months of part A, B, and D access, as
represented in the variables A_MO_CNT, B_MO_CNT and PTD_MO, for each year from
January 1, 2008 to December 31, 2010. The beneficiaries with fee-for-service benefits were
identified by using the HMO_MO and PTD_CNTRCT_ID variables from the MBSF files. The
fee-for-service beneficiaries were defined as those with zero months of HMO coverage and who
were enrolled in “Stand Alone Prescription Drug Plan” from January 1, 2008 to December 31,
2010. Patients were excluded: 1) their encounter was for palliative care, including end of life
care, hospice care and terminal care (identified by ICD-9_CM V66.7) or 2) if they were
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diagnosed with metastatic cancer as those beneficiaries have different drug utilization patterns
which affect their adherence behavior (using ICD-9-CM code 196-199.1); or 3) patients enrolled
in managed care plans.
Variables:
The relevant factors presented in the conceptual model were included as potential
confounders in the different analyses in this study. As previously discussed, those factors have
been shown to impact medication adherence and healthcare utilization in the elderly. Patientrelated variables, including age, gender, and race, were identified from the Beneficiary summary
file (MBSF) at the baseline period. The Medicare data used in this study does not contain
information regarding a beneficiary’s income. The low income subsidy (LIS) variable was used
as a proxy for income. This Medicare program offers the medications at reduced cost for the
beneficiaries who are eligible based on income, family size, and household resources. The LIS
was used in different studies as proxy for the income variable.44,59 The prescription-related
variables, including number of unique medications, were identified from the PDE and drug
characteristics file. The INR monitoring and anticoagulant clinic access were identified by using
the corresponding Current Procedural Terminology (CPT) code in outpatient files. Disease
characteristic variables, including Charlson Comorbidity Index (CCI), CHADS2 (as an indicator
of stroke risk), depression and presence of cognitive impairment during the baseline period (six
months before the index date) were identified from Chronic Condition and Other Chronic
Condition files, inpatient claims, or outpatient claims using corresponding ICD-9-CM codes.
Due to limitations of Medicare dataset, the social support and health belief factors of the
Andersen Behavioral Model were not assessed in this study.
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Age:
The age variable was identified from the MBSF file and was coded as a continuous variable
based on the age of the beneficiary in the baseline period.
Gender:
The gender variable was identified from the MBSF file and was categorized as male or
female.
Race:
The race variable was identified from the MBSF file and was coded as “White”, “Black”, or
“Others”.
Income:
Eligibility for the low income subsidy (LIS) program (as a proxy for income of beneficiary)
was identified using the cost share group variable (CST_SHR_GRP_CD) in the MBSF file. The
cost share code variable indicates the beneficiary’s part D low income subsidy cost sharing group
for each month of the year (from January- December). The LIS program for the Medicare Part D
provides subsidies that lower or eliminate Part D premiums and defines cost sharing for certain
low income beneficiaries. The LIS variable was identified for each beneficiary in the study
cohort in the baseline period and was coded as a categorical variable indicating whether or not
the beneficiary was eligible for the LIS program or not.
Charlson Comorbidity Index (CCI):
The CCI has been used in many retrospective claims studies as an indicator of patient
comorbid conditions, and mortality risk.60 This variable was coded as a continuous variable and
calculated for each beneficiary in the study based on the existence of 17 comorbid conditions.61
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The conditions were identified based on the presence of corresponding ICD-9- CM codes in the
inpatient claims, outpatient claims, the Chronic Conditions file, and the Other Chronic
Conditions CCW files (Table 7). For each beneficiary, corresponding scores were summed based
on the presence of comorbid conditions and assigned as a CCI score. For example, a patient with
peptic ulcer (CCI score of 1) and Myocardial Infarction (CCI score of 1) would have been
assigned a CCI score of 2.
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Table 7:Conditions included in Charlson Comorbidity Index (CCI)
Condition

ICD-9-CM codes

Myocardial infarction

410.x, 412.x

1

Congestive heart failure (CHF)

428.x

1

Peripheral vascular disease

441.x, 443.9, 785.4

1

Cerebrovascular disease

430-438

1

Dementia

290.x

1

Chronic obstructive pulmonary disorder

490-496, 500-505, 506.4

1

Rheumatologic disease

714.81, 725, 710.0, 710.1, 710.4,
714.0- 714.2

1

Peptic ulcer

531.0-531.7, 532.0-532.7, 533.0533.7, 534.0-534.7 ,534.9

1

Mild liver disease and cirrhosis

571.2, 571.4x-571.6

1

Diabetes

250.0-250.3, 250.7

1

Paralysis

342.x, 344.1

1

Diabetes with chronic complications

250.4-250.6

2

Renal disease

582.x,585, 586, 588.x, 583.0-583.7

2

Any malignancy include leukemia or
lymphoma

140-172.9, 174-195.8, 200-208.9

2

Moderate or severe liver disease

572.2-572.8, 456.0-456.21

3

AIDS

042-044

6

Metastatic solid tumor

196-199.1

6
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Score

CHADS2-VASc score:
The CHADS2-VASc score was used as an indicator of stroke risk. The CHADS2-VASc
score is a validated scheme for stratifying stroke risk in AF patients. It is a number from 0 to 9,
where 0 is lowest risk and 9 is highest risk. Stroke risk is calculated depending on the presence
of the following risk factors: Congestive Heart Failure (CHF), Hypertension, age ≥75, Diabetes
Mellitus (DM), history of stroke or TIA symptoms, vascular disease, age 65-74, and being
female. Presentation of each risk factor adds 1 point to the total the CHADS2-VASc score with
the exception of history of a previous stroke and age ≥75 which add 2 points (table 8). The
conditions were identified using inpatient claims, outpatient claims, the Chronic Conditions file,
and the Other Chronic Conditions CCW files using corresponding ICD-9- CM codes. The
variable CHADS2-VASc score was coded as a continuous variable.
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Table 8: CHADS2-VASc score for stratifying stroke risk in AF patients
Criteria

ICD-9-CM codes

Value

History of Congestive Heart Failure (CHF)

428.x

+1

History of Hypertension

401.x-405.x

+1

Age ≥ 75

-

+2

History of Diabetes Mellitus (DM)

250.00, 250.01, 250.02, 250.03,
250.10, 250.11, 250.12, 250.13,
250.20, 250.21, 250.22, 250.23,
250.30, 250.31, 250.32, 250.33,
250.40, 250.41, 250.42, 250.43,
250.50, 250.51, 250.52, 250.53,
250.60, 250.61, 250.62, 250.63,
250.70, 250.71, 250.72, 250.73

+1

Stroke or TIA* Symptoms Previously

433.x1, 434.x1, 435.x, or 436

+2

Vascular disease (e.g. peripheral artery

410.x, 412.x, 441.x, 440.0,
440.1, 440.2, 440.20, 440.21,
440.22, 440.23, 440.29, 440.4,
443.80, 443.81, 443.82, 443.89,
443.9, 785.4

+1

Age 65–74 years

-

+1

Gender (female)

-

+1

disease, myocardial infarction, aortic
plaque)

Depression:
Depression was identified from the Chronic Condition and Other Chronic Condition files
inpatient claims, outpatient claims using corresponding ICD-9- CM code (296.2, 296.3, 311.xx).
This variable was coded as a dummy variable indicating whether or not the beneficiary had
received a diagnosis of clinical depression. This is an important variable to include in the
analysis as depression has been found to affect medication adherence behavior.62,63

45

Cognitive impairment and mental disorders:
This variable denotes the presence of different mental and cognitive conditions. It was
coded as a dummy variable indicating whether or not the beneficiary had any of the following
conditions: dementia (including Alzheimer’s disease), bipolar disorder, or schizophrenia. These
conditions were considered in the analysis as they have been shown to have an impact on
patients’ medication adherence behavior.2,55 This variable was defined using inpatient claims,
outpatient claims, the Chronic Conditions file, and the Other Chronic Conditions CCW files
using corresponding ICD-9- CM codes (table 9).

Table 9: Cognitive impairment conditions and corresponding ICD-9-CM codes
Condition

ICD-9-CM codes

Dementia

Schizophrenia

290.0, 290.10, 290.11, 290.12, 290.13,
290.20, 290.21, 290.3, 290.40,290.41, 290.42,
290.43, 290.8, 290.9
295.xx

Bipolar disorder

296.0, 296.1, 296.4-296.9

Number of unique medications:
This variable was calculated by using prescription claims data in the PDE file. The
unique medication for each beneficiary in the cohort was identified using the GNN variable
(generic name of the drugs). The number of a unique medications was coded as a continuous
variable indicating the number of different medications each beneficiary received in the baseline
period. This is an important variable to consider since increased number of medications and
polypharmacy impact medication adherence behavior.64,65
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Anticoagulant access and INR monitoring:
Access to an anticoagulant clinic was identified by using Healthcare Common Procedure
Coding System codes 85610 or 85730, which represent claims submitted for INR testing or the
prothrombin test. This variable was coded as a continuous variable indicating number of
anticoagulant clinic access or the INR monitoring throughout the index period (12 months after
initiating warfarin therapy).
However, after analyzing the data, we found that almost two thirds of the study
population (68.7%) had missing values for the “anticoagulant clinic access” variable. This is a
limitation of the data source. The data used in this study only capture hospital outpatient claims.
Thus, there was not sufficient information regarding access to an anticoagulant clinic for a large
proportion of the study population. As a consequence, the number of INR monitoring for this
variable could not be determined accurately. In other words, we were unable to capture access to
anticoagulant clinic outside hospitals or clinics (i.e., a private clinic). To overcome this
limitation, an indicator variable was created (0= missing value, 1= a value in the “number
anticoagulant access” variable). The indicator variable was included in all the study models, and
if the significance of the indicator variable was not statistically significant, this was interpreted
as an indication that the missing values in the “anticoagulant clinic access” variable did not
impact study outcomes.
Medicare coverage gap variable:
This variable was calculated using benefit phase variables from the PDE file. Medicare
covers most drug-related costs until the beneficiary reaches a defined threshold each year. When
the beneficiary exceeds that threshold, he/she enters into the coverage gap (i.e., “donut hole”), in
which the Medicare no longer covers the medication expense. The coverage gap variable was
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coded as a dummy variable indicting whether or not the beneficiary was in the coverage gap
during the baseline period. This variable has also been found to impact patient’s medication
adherence behavior.66
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3.1 Specific Aim 1
Specific Aim 1A Identify and describe the trajectory groups of warfarin adherence in
patients with AF in a Medicare population

Specific Aim 1B: Estimate the likelihood of patients belonging to each adherence
trajectory

Specific Aim 1C: Identify characteristics of trajectory members and factors associated with
each adherence trajectory

Outcome measures:
The primary outcome measure was the trajectories of warfarin adherence over the time
period. The Group Based Trajectory Model (GBTM) was used to identify different group
patterns of adherence to warfarin in the study population over a one-year study period and to
estimate likelihood of patients belonging to each adherence trajectory.
Adherence measures:
First, we assessed adherence by creating a supply diary for each patient in the cohort,
indicating if the warfarin was available on each day for 12 months after the index date (first
prescription of warfarin). The supply diary was created by linking all warfarin-related pharmacy
claims based on days’ supply and dispensing date variables in the PDE file. Then, the monthly
proportion of days covered (PDC) was calculated for each patient in the cohort for a period of 12
months after the index date. Monthly PDC was calculated by dividing number of days “covered”
for warfarin in a given month by 30 days:
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Monthly Proportion Days Covered (PDC)=

"#$%&' () *+,- “/(0&'&*” 2&' $(345
67 *+,-

Each patient in the cohort would have 12 calculated PDC values for one year after initiating
warfarin therapy. The PDC was adjusted when the next prescription was filled before the end of
supply of the previous fill. For example, figure 3 shows the case in which the second claim, filled
on Oct. 10, 2008, occurs before the end of supply of the first claim (Sept.15, 2008). In this case,
the PDC was calculated by adjusting the overlapping days’ supply and shifting the fill date of the
second claim forward until the end of supply of the first claim (i.e., the new fill date of the
second claim, thus becomes Oct.15, 2008).67

Figure 3: Example of adjusted PDC for overlapping days’ supply
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Group based trajectory model:
The 12 monthly measures for warfarin adherence for each patient in the cohort were
modeled using GBTM. Each patient was classified into a trajectory group based on his/her
adherence pattern over the one-year period. When running the trajectory model, several multiple
regression models were estimated simultaneously, where the outcome was the probability of
being adherent (monthly PDC) and the independent variable was time in months.
The GBTM is an application of finite mixture models and the estimation of model parameters is
a product of the maximum likelihood function. These parameters determine the shape of the
trajectories and the size of the groups. The GBTM estimates the posterior probabilities or the
membership probabilities for each beneficiary in the cohort, which in turn determine the
assignment of the beneficiaries to the trajectory groups according to the highest membership
probability.32
The PROC TRAJ function of SAS 9.4® was used in this study to run the GBTM. The PROC
TRAJ procedure is not part of the base SAS software, and was downloaded separately from B.
Jones’s website.68
The main inputs necessary to run the GBTM are:
1. Outcome variable: the 12 repeated measures of PDC for each patient in the cohort.
2. Independent variable: the 12 time variables (month1-month12), which patient’s
adherence were measured over.
3. Distribution of the outcome variable: as the PDC is proportion data (censored data), so
the distribution was specified as censored normal distribution.
4. Number of groups.
5. Order of each equation that describes change over time for each group.

51

The model fitting process of the GBTM is iterative and required running the model
several times, changing the number of groups and assigned order each time, in order to achieve
the best fitted model for the data. The model fit process can be summarized in the following
steps:
1. Determining the maximum number of groups.
2. Select the appropriate order for each group and run models, starting with one group
model until maximum assigned number of groups is reached in a stepwise manner.
3. Select the the model with the appropriate number of groups that best fits the data.
In step one, the maximum number of groups can be determined based on the literature.
In this study, the maximum number of groups was limited to six groups for simplicity of
interpretations and to avoid small size of trajectory groups.44,69
In the second step, the shape of the trajectory for each group over time was determined
based on the proper order of each equation. According to the recommendation by Nagin et al.,
each group should be assigned to second order (quadratic order) at the beginning of the analysis
and then changing it until reaching an appropriate order for the best model. The PROC TRAJ
function can model up to a fourth order polynomial. As a general rule, one group model with
quadratic order is tested first. If the parameters of the single quadratic model are not significant,
then another model is run by changing the order of the group from quadratic to linear or cubic
until getting significant parameters. If the parameters of the single quadratic model are
significant, then a two groups quadratic model is performed. This process is repeated with
additional number of the trajectory groups until the six groups model (i.e., maximum number of
groups). In this study, the parameters of the quadratic order for all six models were significant so
there was no need to change the order of the groups to linear, cubic, or quartic.
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After performing the second step, six models were produced with different number of
groups and shapes of trajectories. The selection of the final model is based on three main criteria:
1) Bayesian information criteria (BIC); 2) the proportion of beneficiaries in each group is not
less than 5% of total sample; and 3) Nagin’s criteria.
The BIC values are estimated for each model and considered the fit index when comparing
between models. To compare between competing models, the log Bayes factor was used and is
calculated by subtracting the BIC of the simple model (model with fewest groups) from each
successive, more complex model (model with more groups) and multiplying it by two:70,71
2∆BIC = 2 x [ BIC (complex) – BIC (simple)]
The interpretation of the log Bayes factor in terms of model fit is explained according to
guidelines by Jones et al., (table 10)
Table 10: Interpretation of logged Bayes factor (2*∆BIC) for model selection
2*∆BIC

Evidence against Ho

0 to 2

Not worth mentioning

2 to 6

Positive

6 to 10

Strong

> 10

Very strong

According to this guideline, a logged Bayes factor value of 0 to 2, for example, indicates
weak evidence that a more complex model has a better fit compared to the simple model. While
a value of more than ten is interpreted as very strong evidence of better fit of the complex model.
First, the model with two trajectory groups is compared to the single group model by calculating
log Bayes factor. If the value is indicative of a better fit (i.e., 2*∆BIC > 2), then the two groups
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model is compared to three groups model. This process is continued, by comparing to each the
increasingly complex model, until there is no more evidence for improvement in the model fit.
Once the number of trajectory groups was determined, the beneficiaries were classified into
the groups based on the highest posterior probability (maximum-probability assignment rule).27,34
An example for applying the maximum-probability assignment rule to assigned beneficiaries to
groups is shown in table 11. This process is done automatically by the PROC TRAJ function in
SAS.
Table 11: Example of assigning beneficiaries to trajectory groups based on the maximumprobability assignment rule
Beneficiary ID
1

Probability Probability
to group 1 to group 2
0.21
0.63

Probability
to group 3
0.02

Probability
to group 4
0.14

Assigned
group
2

2

0.24

0.02

0.07

0.67

4

3

0.54

0.11

0.33

0.02

1

After selecting the appropriate number of groups according the logged Bayes factor, the
proportion of the beneficiaries in each group is evaluated. Ideally, the proportion of beneficiaries
in each group should not be less than 5% of the total sample.
The third criteria for model selection is Nagin’s criteria for model adequacy which indicates
how well or precisely the beneficiaries are assigned to each trajectory group based on average
posterior probability.27,44 The average posterior probability is an indicator of the internal
reliability of the model. It is calculated for each group and equals the average assigned posterior
probabilities of the beneficiaries to trajectory using the maximum-probability assignment rule.
An average posterior probability greater of 0.7 for all the groups is recommended.
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The major outputs for the trajectory model are the appropriate trajectory groups of
warfarin adherence, the membership probability for each beneficiary in each group, and
graphical illustration of trajectory curves, with PDC values on the y-axis and time (months) on
the x-axis.
Statistical analysis:
Baseline characteristics of the cohort, stratified by trajectory group, were described, with
means and standard deviation calculated for continuous variables and percentages for categorical
variables.
To describe associations between patients’ characteristics, including confounders in the
conceptual framework, and trajectory groups, a multinomial regression model was used:
Log (9(;<=>?@) 9(BCD ;<=>? ∗)) = β0 + β1 AGE + β2 GENDER + β3 RACE + β4 LIS +
β5 COVERAGE_GAP + β6 CHADS2-VASc + β7 CCI +β8 DEPRESSION+β9

COGNITIVE_IMPAIRMENT+ β10 NO_MEDICATION+ β11 INR_MONITORING
*Ref group: perfectly adherent
The outcome of interest was the odds of being in a given group compared to a perfectly
adherent group. Odds ratios and 95% Confidence intervals (95% CI) from the multinomial
regression model were reported. All statistical analyses were conducted using SAS 9.4® and a
significance level of α ≤ 0.05 was assigned.
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3.2 Specific Aim 2
Specific Aim 2A: Estimate the rates of hospitalizations related to a stroke or bleeding event
(clinical outcomes) associated with each adherence trajectory

Specific Aim 2B: Evaluate the association between warfarin adherence trajectory group
membership and the likelihood of hospitalization due to a stroke or bleeding event
Outcome measures:
For Specific Aim 2, the outcome of interest is time to first hospitalization related to AF
or warfarin therapy. In this study, a hospitalization event is defined as the first admission due to a
bleeding event or stroke in the follow-up period (one year after first warfarin fill). The follow-up
was restricted to only one year to limit the assessment to hospitalization events occurring at the
same time as the observed adherence patterns. The hospitalization events were identified from
the corresponding ICD-9-CM codes as the primary discharge diagnosis for hospitalization or
admitting diagnosis in the inpatient file. The defined ICD-9 codes are listed in table 12.
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Table 12: ICD-9 codes and corresponding definitions for hospitalization events
Condition
Major Bleeding
Gastrointestinal bleeding

Non-traumatic intracranial

ICD-9 codes

456.0, 456.20, 530.21, 530.7, 530.82, 531.0x,
531.2x, 531.4x, 531.6x, 532.0x, 532.2x, 532.4x,
532.6x, 533.0x, 533.2x, 533.4x, 533.6x, 534.0x,
534.2x, 534.4x, 534.6x, 535.01, 535.11, 535.21,
535.31, 535.41, 535.51, 535.61, 535.71, 537.83,
537.84, 562.02, 562.03, 562.12, 562.13, 568.81,
569.3, 569.85, 578.x
430, 431, 432.x

hemorrhage
Traumatic intracranial hemorrhage

852.x, 853.x

Bleeding from other sites

423.0, 459.0, 596.7, 599.71, 719.1x, 784.8, 786.3

Stroke
Ischemic stroke

433.x1, 434.x1, or 436

Transit ischemic attack (TIA)

435.X

Systemic embolism

444.x

Statistical analysis:
Baseline characteristics of the cohort were described between patients who experienced
hospitalization events in the follow-up period and those that did not have an event, with means
and standard deviation for continuous variables and percentages for categorical variables. In
order to examine the association between trajectory groups and the first hospitalization event,
while controlling for potential confounders, a multivariable Cox proportional hazards model was
used:
Log [h(t|x)] = β0 + β1 TRAJ* + βX X**
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[h(t|x)]: hazard ratio of hospitalization
*TRAJ: Warfarin adherence trajectory groups
**X: Confounders
The dependent variable in the model is time to first hospitalization event due to bleeding
or stroke events in the follow-up period. Time units were coded as days starting after one year
from the index date. Beneficiaries were followed until the first hospitalization event, death, or
end of follow-up period. Cases were coded as censored if the hospitalization event had not
occurred by the end of the follow up period, or if the beneficiary died. The proportion of patients
who experienced events was presented by trajectory group. Results for the association between
adherence trajectories and time to first hospitalization were reported as a hazard ratio (HR) and
95% CI. Statistical significance was defined as α ≤ 0.05.
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3.3 Specific Aim 3
Specific Aim 3A: Estimate the AF-related costs for each adherence trajectory group

Outcome measures:
The primary outcome for this aim was AF-related costs associated with each trajectory
adherence group through the follow-up period. In this study, the costs included were direct
medical costs from the societal perspective. The direct medical costs associated with AF were
calculated by including cost of 1) anticoagulant clinic services, 2) outpatient visits, and 3)
inpatient visits related to bleeding or thromboembolic events. Use of anticoagulant clinic
services was identified using corresponding CPT codes for INR testing (CPT codes
'85610','85730'). AF-related inpatient and outpatient visits were identified using corresponding
ICD-9-CM codes for AF, bleeding or thromboembolic events in the principal diagnosis,
admitting diagnosis or the first three diagnosis variables in the inpatient and outpatient Medicare
files (Table 8). Total cost was computed by summing the amount paid by Medicare, the
beneficiary and other third-party payers, if any. The amount paid by Medicare, other third party
payers, and beneficiary were obtained from the base inpatient and outpatient files, but the
amount paid by the beneficiary for anticoagulant clinic was identified from the Revenue Center
files and were linked to the base file by a unique claim identifier (CLM_ID). The different cost
components were calculated as follows:
FCGHIJ<C KhJ<C = @L=>MN ?JHG OP FCGHIJ<C + (QHCL JL=>MN ?JHG R>LOC< =D GJPK HM
ISJHL)
TCMeDHIHJ<P KhJ<C = QCG>INHOSC + U=HMK><JMIC + TS==G GCG>ItHOSC
V=NJS amount paid = FCGHIJ<C KhJ<C + TCMeDHIHJ<P KhJ<C + VhH<G ?J<NP ?JPLCMN
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All costs associated with emergency department visits (ED) were already captured in the
inpatient or outpatient billing depending if the beneficiary was admitted (inpatient) or discharged
(outpatient) after their ED visit.
All positive cost data were presented in $US and inflated to 2018 currency values by using the
US Healthcare inflation rate from the Bureau of Labor Statistics (Appendix B).72
Statistical analysis:
Direct medical costs associated with each adherence trajectory were calculated. Cost
components included in the analysis were costs related to inpatient visits, outpatient visits, and
INR monitoring. The mean of total costs related to AF associated with each trajectory group
were reported in addition to a breakdown of cost components stratified by adherence trajectory.
An ANOVA analysis was performed to test for differences in total cost and cost components
(inpatient visits, outpatient visits, and INR monitoring) between different trajectory groups. All
analyses were performed using SAS 9.4 software. A P-values less than 0.05 denoted statistical
significance.
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3.4 Sensitivity Analysis
To confirm robustness of the study results, two sensitivity analyses were conducted. As
medication adherence can have an impact on short-term clinical outcomes, a three months’
follow-up period was examined in place of the one-year follow-up period used in the main
analysis. Another sensitivity analysis was performed defining hospitalization events due to stroke
or bleeding using corresponding ICD-9 codes in the secondary discharge diagnosis field instead
of the primary diagnosis field.
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Chapter 4: Results
In this section the final study population is described. This is followed by the description
of the results for each individual aim.

4.1 Study Population
From the random sample of Medicare beneficiaries, 50,636 beneficiaries met the
eligibility criteria, i.e., AF patients, age ≥65, with three years of continuous enrollment in
Medicare Part A, B and D. Of those, 3,246 beneficiaries were identified as new users of warfarin
with at least two prescriptions and were identified to be the population of interest (Figure 4). On
average beneficiaries were 78 years old, 63% women, and 91% white (Table 13).
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Total Medicare beneficiaries in 2008
(2,631,893)

Include FFS beneficiaries, age ≥65 years old
with full coverage of Medicare part A, B, and D (n=650,399)

Beneficiaries with at least one inpatient or two outpatient
claims for AF in the baseline period (n= 63,870)

Exclude beneficiaries with:
• Prior diagnosis of metastatic cancer
• Palliative care
• Not continuously enrolled in
Medicare

Included Beneficiaries (n=50,636)

Exclude beneficiaries who had:
• Warfarin claim in the baseline period
(prevalent users)
• With less than two prescriptions of
warfarin

Final population (n=3,246)

Figure 4: Eligibility flow chart for the study cohort
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Table 13: Baseline characteristics for the study cohort
Characteristics

Total
(3,246)

Age
Mean (SD)
78.42 (7.02)
Gender (%)
Male
37.34
Female
62.66
Race (%)
White
91.74
Black
3.82
Others
4.44
LIS eligibility (%)
No
72.64
Yes
27.36
CCI
Mean (SD)
3.06 (2.28)
Median (min-max)
3.00 (0-13)
CHADS2-VASc score
Mean (SD)
5.10 (1.74)
Median (min-max)
5.00 (1-9)
Depression (%)
No
80.62
Yes
19.38
*Abbreviation used: LIS eligibility: Low Income Subsidy eligibility, CCI: Charlson Comorbidity
Index
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Table 13: Continued
Characteristics

Total
(3,246)

Cognitive impairment and mental disorders (%)
No
Yes
Number of chronic medications
Mean (SD)
Median (min-max)
Coverage Gap
Yes
No
Anticoagulant access (%)
Yes
No

91.25
8.75
13.41 (6.15)
12.50 (1-39)
40.70
59.30
32.10
67.90
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4.2 Specific Aim 1
Specific Aim 1A: Describe the trajectory groups of warfarin adherence in patients with AF
in Medicare population
Specific Aim 1B: Estimate the likelihood of patients belonging to each adherence
trajectory
Six trajectory models were performed ranging from one group to six groups (figure 5). As the
number of groups increased, there was an improvement in the statistical fit (i.e., the absolute BIC
value getting lower indicating better fit). The Bayes factor and estimated group proportions were
used to determine the best GBTM model (Table 14). The six groups model provided the best
statistical fit based on the Bayes factor, and the estimated proportion of the beneficiaries in each
group were more than 5% of the total study population. Thus, the six groups model was selected
as the final model. The parameter estimates of the final model were all significant and are
presented in Table 15.
Additionally, Nagin’s criteria for assessing the final model adequacy in assigning the
beneficiaries in each trajectory group was checked, and indicated that the six group model
performed well in distinguishing between beneficiaries with different adherence patterns (i.e.,
average posterior probability for each trajectory group is ≥ 0.7) (Table 16).
Figure 6 illustrates six distinct adherence patterns for warfarin during the first year after
initiating treatment. The six adherence trajectories were described and labeled based on the
timing of discontinuation of warfarin and the level of the PDC: 1) Rapid decline non-adherence
group (11.5%, mean PDC: 0.22), 2) moderate non-adherence group (24%, mean PDC: 0.56), 3)
rapid decline then increasing adherence group (6.8%, mean PDC: 0.85), 4) moderate decline
non-adherence group (8.2%, mean PDC: 0.51), 5) slow decline non-adherence group (24.3%,
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mean PDC: 0.84), and 6) perfect adherence group (25.3%, mean PDC: 0.99) (table 16). Table 17
shows the baseline characteristics of beneficiaries stratified by trajectory groups. Relative to
other adherence groups, the beneficiaries in the “rapid decline then increase adherence group”
were more likely to be male. Overall, beneficiaries in the “perfect adherence group” were more
likely to be eligible for the LIS program and to suffer from mental health conditions.
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Figure 5: Trajectory models using one to six groups. In each plot, the solid lines represent the predicted probability of adherence in
each group, and the dotted lines represent the observed proportion. The proportion of beneficiaries in each group is given under each
graph
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Table 14: Bayesian Information Criterion (BIC) values and percentage of patient in each group for the six models
Model

BIC

Bayes
factor

Percentage of patients in each group
Group 1

Group 2

Group 3

Group 4

Group 5

Group 6

1 group

-37,135.97

-

100%

-

-

-

-

-

2 groups

-30,902.02

12,467.9

45.37%

54.63%

-

-

-

-

3 groups

-28,608.53

4,586.98

16.42%

46.80%

36.78%

-

-

-

4 groups

-27,667.02

1,883.02

12.90%

8.77%

41.20%

37.13%

-

-

5 groups

-27,139.29

1,055.46

11.89%

8.50%

27.39%

27.88%

24.34%

-

6 groups

-26,778.85

720.88

11.53%

23.95%

6.79%

8.17%

24.28%

25.27%
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Table 15: Parameter estimates of adherence trajectories for the six-groups model
Trajectory group
1. Rapid decline non-adherence
group

2. Moderate non-adherence group

3. Rapid decline then increasing
adherence group

4. Moderate decline nonadherence group

5. Slow decline non-adherence
group

6. Perfect adherence group

Parameter order

Estimate

P-value

Intercept

2.59

<0.001

Linear

-0.87

<0.001

Quadratic

0.04

<0.001

Intercept

1.40

<0.001

Linear

-0.28

<0.001

Quadratic

0.02

<0.001

Intercept

1.93

<0.001

Linear

-0.58

<0.001

Quadratic

0.07

<0.001

Intercept

1.46

<0.001

Linear

0.18

<0.001

Quadratic

-0.05

<0.001

Intercept

1.80

<0.001

Linear

-0.12

<0.001

Quadratic

0.01

0.009

Intercept

1.64

<0.001

Linear

0.20

<0.001

Quadratic

-0.01

<0.001
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Table 16: Model fit statistics for the six-groups model
Trajectory group

Group size

PDC

N

%

Mean

SD

Average Posterior
probability*
Mean
SD

1. Rapid decline group

378

11.53%

0.22

0.08

0.97

0.09

2. Moderate non-adherence group

787

23.95%

0.56

0.14

0.91

0.14

3. Rapid decline then increasing
adherence group
4. Moderate decline group

216

6.79%

0.85

0.09

0.87

0.16

262

8.17%

0.51

0.10

0.94

0.11

5. Slow decline group

760

24.28%

0.84

0.07

0.89

0.14

6.Perfect adherent group

843

25.27%

0.99

0.02

0.94

0.13

*Average posterior probability: represents how well beneficiaries are classified into trajectory groups. An average posterior
probability greater than 0.7 indicates a good model fit
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Warfarin adherence over one-year
1
0.9
0.8

PDC

0.7
0.6
0.5
0.4
0.3
0.2
0.1
0
1

2

3

4

5

6

7

8

9

Time in months
Group 1: Rapid decline non-adherence

Group 2: Moderate non-adherence

Group 3: Rapid decline then increasing adherence

Group 4: Moderate decline non-adherence

Group 5: Slow decline non-adherence

Group 6: perfect adherence

Figure 6:Warfarin adherence trajectories in the 12 months following initiation (Final model)
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Table 17: Baseline characteristics of study population stratified by adherence trajectory groups
Characteristics 1. Rapid
decline
group (n=
378)

2. Moderate
nonadherence
group
(n=787)

3. Rapid
decline then
increasing
adherence
group
(n=216)

Age
Mean (SD)
78.13 (7.10)
78.02 (6.57)
78.90 (7.24)
Gender (%)
Male
38.10
37.23
43.98
Female
61.90
62.77
56.02
Race (%)
White
90.48
93.14
93.98
Black
3.44
3.81
2.78
Others
6.08
3.05
3.24
LIS eligibility
(%)
No
74.60
77.51
73.61
Yes
25.40
22.49
26.39
*Abbreviation used: LIS eligibility: Low Income Subsidy eligibility
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4. Moderate
decline
group
(n=262 )

5. Slow
decline group
(n=760)

6. perfect
adherence
group
(n=843)

Total
(3,246)

78.13 (7.35)

78.31 (6.90)

79.01 (7.32)

78.42 (7.02)

37.40
62.60

39.61
60.39

33.33
66.67

37.34
62.66

89.69
3.05
7.25

91.18
4.61
4.21

91.58
3.80
4.63

91.74
3.82
4.44

73.28
26.72

73.68
26.32

65.84
34.16

72.64
27.36

Table 17: Continued
Characteristics 1. Rapid
decline
group (n=
378)

2. Moderate
nonadherence
group
(n=787)

3. Rapid
decline then
increasing
adherence
group
(n=216)

CCI
Mean (SD)
3.23 (2.19)
3.07 (2.32)
2.93 (2.23)
Median
3.00 (0-10)
3.00 (0-12)
3.00 (0-10)
(min-max)
CHADS2VASc score
Mean (SD)
5.04 (1.70)
5.11 (1.69)
4.98 (1.71)
Median
5.00 (2-9)
5.00 (1-9)
5.00 (1-9)
(min-max)
Depression
(%)
No
80.69
82.97
80.09
Yes
19.31
17.03
19.91
*Abbreviation used: CCI: Charlson Comorbidity Index
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4. Moderate
decline
group
(n=262 )

5. Slow
decline
group
(n=760)

6. perfect
adherence
group
(n=843)

Total
(3,246)

3.14 (2.33)
3.00 (0-11)

3.00 (2.32)
3.00 (0-13)

3.03 (2.26)
3.00 (0-11)

3.06 (2.28)
3.00 (0-13)

4.95 (1.72)
5.00 (1-9)

5.06 (1.79)
5.00 (1-9)

5.23 (1.79)
5.00 (1-9)

5.10 (1.74)
5.00 (1-9)

77.10
22.90

81.97
18.03

78.41
21.59

80.62
19.38

Table 17: Continued
Characteristics 1. Rapid
decline group
(n= 378)

Cognitive
impairment
(%)
No
Yes
Number of
chronic
medications
Mean (SD)
Median
(min-max)
Coverage Gap
Yes
No

2. Moderate
nonadherence
group
(n=787)

3. Rapid
decline then
increasing
adherence
group
(n=216)

4. Moderate
decline
group
(n=262 )

5. Slow
decline group
(n=760)

6. perfect
adherence
group
(n=843)

Total
(3,246)

91.27
8.73

94.28
5.72

91.67
8.33

90.08
9.92

92.24
7.76

87.78
12.22

91.25
8.75

13.68 (6.00)
13.00 (3-37)

13.27 (6.20)
13.00 (1-39)

12.69 (5.62)
12.00 (3-32)

13.90 (6.22)
13.00 (2-34)

13.11 (5.97)
12.00 (3-37)

13.70 (6.43)
13.00 (2-39)

13.41 (6.15)
12.50 (1-39)

39.95
60.05

39.26
60.74

41.20
58.80

41.22
58.78

41.97
58.03

40.93
59.07

40.70
59.30
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Table 17: Continued
Characteristics

1. Rapid
2. Moderate
decline group non(n= 378)
adherence
group
(n=787)

Anticoagulant
access (%)
Yes
32.28
No
67.72

34.56
65.44

3. Rapid
decline then
increasing
adherence
group
(n=216)
29.17
70.83

4. Moderate
decline
group
(n=262 )

28.63
71.37
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5. Slow
decline group
(n=760)

31.58
68.42

6. perfect
adherence
group
(n=843)

32.03
67.97

Total
(3,246)

32.10
67.90

Specific Aim 1C: Identify patients’ characteristics and factors associated with each adherence
trajectory
The results of the multinomial logistic regression model for identifying predictors of
adherence trajectory groups are presented in Table 18. No significant differences were found
between adherence trajectories and demographic characteristics, presence of clinical depression,
number of chronic medications, or access to an anticoagulant clinic. However, Hispanic, Asian,
or North American natives together had twice the odds of being in the “moderate decline” group
compared to the “perfect adherence” group (others vs. white OR: 2.01, 95% CI: 1.11-3.63). LIS
eligibility was found to be a significant predictor of adherence trajectory groups. Specifically,
being eligible for the LIS program was associated with higher odds of being in “perfect
adherence” group compared to other groups. Having more cognitive conditions was associated
with lower risk for being in the “moderate non-adherent” and “slow decline” groups relative to
the “perfect adherence” group (OR: 0.51, 95%CI: 0.35-0.74, OR: 0.68 95%CI: 0.48-0.97,
respectively). Keeping other covariates constant, with every unit increase in the CCI there were
increased odds of being in the “rapid decline” and “moderate decline” group” relative to the
“perfect adherent” group (OR:1.12, 95%CI: 1.04-1.2, OR: 1.11, 95%CI: 1.02-1.2, respectively).
Moreover, with every unit increase in the stroke risk score (CHADS2-VASc score), there was a
15% decrease in the odds of being in “moderate decline” group compared to being in the “perfect
adherence” group (OR: 0.85, 95% CI: 0.76-0.96). The odds for being in the “slow decline” group
compared to the “perfect adherence” group were 29% higher for beneficiaries who had been in
the insurance gap (OR: 1.29, 95% CI: 1.02-1.63).
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Table 18: Multinomial Logistic Regression: Predictors of Adherence Trajectory Group
Characteristics

1. Rapid
decline group,
OR (95%CI)

Age

0.99 (0.97-1.01)

2. Moderate
non-adherence
group, OR
(95%CI)

3. Rapid
4. Moderate
decline then
decline group,
increasing
OR (95%CI)
adherence
group, OR
(95%CI)
0.98 (0.96-1.00) 1.01 (0.98-1.03)
1.00
(0.97-1.02)

5. Slow decline
group, OR
(95%CI)

6. perfect
adherence
group
(Ref)

0.99 (0.98-1.01)

1

Gender
Male

Ref

Ref

Ref

Ref

Ref

Ref

1.03 (0.77-1.38)

0.98 (0.78-1.24)

0.70 (0.49-1.00)

1.09 (0.781.52)

0.86 (0.68-1.09)

1

White

Ref

Ref

Ref

Ref

Ref

Ref

Black

1.11 (0.56-2.19)

1.52 (0.74-2.12)

0.98 (0.36-2.21)

1.01 (0.452.29)

1.50 (0.90-2.49)

1

Others

1.70 (0.98-2.95)

0.84 (0.49-1.43)

0.73 (0.33-1.77)

2.01 (1.113.63)

1.07 (0.65-1.76)

1

LIS eligibility

0.60 (0.44-0.82)

0.58 (0.45-0.73)

0.79 (0.54-1.14)

0.62 (0.440.88)

0.69 (0.54-0.88)

1

CCI

1.12 (1.04-1.2)

1.05 (0.99-1.11)

1.04(0.95-1.14)

1.11 (1.02-1.2)

1.03 (0.97-1.10)

1

CHADS2-VASc
score

0.91 (0.82-1.01)

1.01 (0.93-1.10)

0.96 (0.84-1.09)

0.85 (0.760.96)

0.99 (0.90-1.07)

1

Female
Race

*Abbreviation used: LIS eligibility: Low Income Subsidy eligibility, CCI: Charlson Comorbidity Index
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Table 18: Continued
Characteristics

1. Rapid
decline group,
OR (95%CI)

2. Moderate
non-adherence
group, OR
(95%CI)

4. Moderate
decline group,
OR (95%CI)

5. Slow decline
group, OR
(95%CI)

0.83 (0.64-1.08)

3. Rapid
decline then
increasing
adherence
group, OR
(95%CI)
1.11 (0.75-1.65)

Depression

0.91 (0.66-1.26)

History of
cognitive
impairment and
mental disorders
Number of chronic
medications

1.13 (0.801.62)

0.91 (0.70-1.81)

1

0.79 (0.51-1.21)

0.51 (0.35-0.74)

0.70 (0.40-1.22)

0.90 (0.561.46)

0.68 (0.48-0.97)

1

1.00 (0.97-1.03)

0.99 (0.97-1.01)

0.97 (0.94-1.00)

1.01 (0.981.03)

0.98 (0.96-1.00)

1

History of being in
the insurance gap

1.03 (0.77-1.37)

1.10 (0.87-1.39)

1.38 (0.97-1.97)

1.05 (0.751.46)

1.29 (1.02-1.63)

1

Having access to
anticoagulant
clinic

0.95 (0.73-1.25)

1.11 (0.89-1.38)

0.88 (0.62-1.23)

0.81 (0.591.11)

0.97 (0.78-1.21)

1
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6. perfect
adherence
group
(Ref)

4.3 Specific Aim 2
Specific Aim 2A: Estimate the rates of hospitalizations related to a stroke or bleeding event
(clinical outcomes) associated with each adherence trajectory

Overall, 7.5% of the sample population had an AF-related hospitalization event (figure 7). As
shown in table 19, beneficiaries who had AF-related hospitalization had slightly lower overall
PDC (PDC for hospitalized: 0.68, non-hospitalized: 0.71). The AF-related hospitalization events
in the 12-month period following therapy initiation was least frequent in the “rapid decline then
increasing adherence”, “slow decline”, and “perfect adherent” groups (6.02%, 6.18%, and
7.35%, respectively) and highest in the “moderate decline” and “rapid decline” groups (9.54%,
and 8.73%, respectively).

Figure 7: Percentage of AF-related hospitalization after one year of initiating warfarin therapy
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Table 19: Baseline characteristics for hospitalized compared to non-hospitalized patients
Characteristics

Hospitalized
(7.46%)

Non-hospitalized
(92.54% )

1. Rapid decline group

8.73%

91.27%

2. Moderate non-adherence group

7.88%

92.12%

3. Rapid decline then increasing adherence group

6.02%

93.98%

4. Moderate decline group

9.54%

90.46%

5. Slow decline group

6.18%

93.82%

6.Perfect adherent group

7.35%

92.65%

0.68

0.71

78.95% (7.02)

78.38 (7.02)

Male

5.36%

94.64%

Female

8.70%

91.30%

White

7.32%

92.68%

Black

7.26%

92.74%

Others

10.42%

89.58%

No

6.70%

93.30%

Yes

9.46%

90.54%

Adherence trajectories (%)

Overall PDC
Age
Mean (SD)
Gender (%)

Race (%)

LIS eligibility (%)

*Abbreviation used: LIS eligibility: Low Income Subsidy eligibility
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Table 19: Continued
Characteristics

Hospitalized
(7.46%)

Non-hospitalized
(92.54% )

CCI
Mean (SD)

4.04 (2.30)

2.98 (2.26)

Median (min-max)

4.00 (0.00-11.00)

3.00 (0.00-13.00)

Mean (SD)

5.83 (1.67)

5.04 (1.74)

Median (min-max)

6.00 (2.00-9.00)

5.00 (1.00-9.00)

No

7.11%

92.89%

Yes

8.90%

91.10%

7.53%

92.47%

6.69%

93.31%

Mean (SD)

14.50 (6.45)

13.32 (6.12)

Median (min-max)

13.00 (2.00-34.00)

12.00 (1.00-39.00)

Yes

7.34%

92.66%

No

7.53%

92.47%

Yes

7.77%

92.23%

No

7.30%

92.70%

CHADS2-VASc score

Depression (%)

Cognitive impairment and mental
disorders (%)
No
Yes
Number of chronic medications

Coverage Gap

Anticoagulant access (%)

*Abbreviation used: CCI: Charlson Comorbidity Index
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Specific Aim 2B: Evaluate the association between warfarin adherence trajectory group
membership and the likelihood of hospitalization due to a stoke or bleeding event

Results for the Cox proportional hazard model are presented in table 20. Even though no
statistically significant differences were found in the hazard of hospitalization between the
adherence groups, there were higher odds of hospitalization among the lower adherence groups
(moderate adherence, moderate decline non-adherence and the rapid decline non-adherence),
compared to perfect adherence group. Beneficiaries in the “rapid decline” and “moderate nonadherence” groups had 23% and 34% higher odds of being hospitalized in the year after
initiating warfarin treatment compared to the “perfect adherence” group, respectively.
Other factors associated with an increased risk of AF-related hospitalization events were
gender, Charlson comorbidity index, CHADS2-VASc score, and being in the Medicare coverage
gap. In the study population, females had 41% higher risk of being hospitalized compared to
males (P-value = 0.03). After adjustment for all covariates, with every unit increase in the
Comorbidity Index and the stroke risk score there is a 16% and 17%, respectively, higher odds of
being hospitalized in the year after initiating warfarin treatment (P-values <0.0001, <0.005
respectively).
Finally, the proportionality assumption for the Cox proportional model was evaluated by
examining the log minus log curve and the Schoenfeld residuals. Based on the graphs and the pvalue for the Schoenfeld residuals, the proportionality assumption of the model was satisfied.
(See Appendix C, D, and E)
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Table 20: Multivariable Cox Proportional Hazard Models of Adherence Trajectories of warfarin
and risk of AF-related hospitalization
Characteristics

AF-related hospitalization
HR (95%CI)

P-value

REF

REF

1. Rapid decline group

1.23 (0.80-1.88)

0.35

2. Moderate non-adherence group

1.10 (0.77-1.56)

0.62

3. Rapid decline then increasing adherence group

0.88 (0.48-1.61)

0.68

4. Moderate decline group

1.34 (0.84-2.14)

0.22

5. Slow decline group

0.87 (0.59-1.27)

0.47

Age

0.99 (0.97-1.04)

0.51

Gender (ref= Male)

1.41 (1.03-1.94)

0.03

REF

REF

Black

0.65 (0.33-1.29)

0.22

Others

1.29 (0.75-2.23)

0.36

LIS eligibility

1.26 (0.94-1.69)

0.13

CCI

1.16 (1.08-1.24)

<0.0001

CHADS2-VASc score

1.17 (1.05-1.30)

<0.005

Depression

1.02 (0.75-1.40)

0.89

Cognitive impairment and mental disorders

0.67 (0.41-1.08)

0.10

Number or chronic medications

1.00 (0.97-1.02)

0.77

Coverage gap

0.70 (0.52-0.95)

0.02

AC indicator

0.86 (0.65-1.14)

0.29

Trajectory group (ref= perfect adherent)

Race (ref= White)

*Abbreviation used: LIS eligibility: Low Income Subsidy eligibility, CCI: Charlson Comorbidity Index
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4.4 Specific Aim 3
Specific Aim 3A: Estimate the AF-related costs for each adherence trajectory group
Table 21 presents direct AF-related health care costs for Medicare beneficiaries treated with
warfarin during the follow-up period stratified by adherence trajectory groups. Because the cost
data were predictably extremely right-skewed (Figure 8) and there was a large number of zero
values (67%-83%), the cost variables were log-transformed. By taking the log, the cost data
become more standardized and demonstrate closer to a normal distribution This transformation
leads to more reliable estimates and the variation in the means is reduced. Table 22 presents log
direct AF-related health care costs for Medicare beneficiaries treated with warfarin stratified by
adherence trajectory groups.
Table 22 presents log direct AF-related health care costs for Medicare beneficiaries treated
with warfarin stratified by adherence trajectory groups.
The log of monitoring cost and outpatient cost were found to differ significantly among the
trajectory groups (p-value<0.0001, 0.0013, respectively). Mean log monitoring costs were found
to be highest among beneficiaries in the “perfect adherence” and “moderate non-adherence”
groups, and lowest among the “moderate decline” group. The mean log outpatient cost was
significantly higher among the “moderate non-adherence” group compared to other trajectory
groups (table 22).
Beneficiaries in the “rapid decline” group were found to have the highest inpatient costs as
compare to the other trajectory groups, but the differences were not statistically significant (pvalue= 0.33). Similar to mean log outpatient cost, mean log total cost was higher among the
“moderate non-adherence” group compared to other trajectory groups, but this difference was
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not statistically significant (p-value = 0.23). Among all the trajectory groups, the majority of the
costs were attributed to inpatient costs.

Figure 8: Distribution of total AF-related direct medical cost
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Table 21: Mean AF-related costs stratified by trajectory groups
Variable

1. Rapid
decline
group,
Mean (SD)

2. Moderate
nonadherence
group,
Mean (SD)

3. Rapid decline
then increasing
adherence
group,
Mean (SD)

4. Moderate
decline
group,
Mean (SD)

5. Slow
decline
group,
Mean (SD)

6. perfect
adherence
group,
Mean (SD)

P-value

Inpatient cost

2,756.61
(7,480.18)

2,686.93
(9,069.58)

1,676.31
(5,637.46)

2,400.38
(6,907.50)

2,239.20
(9,511.57)

2,555.00
(9,987.34)

0.6146

Outpatient cost

181.02
(977.28)

349.40
(2741.49)

135.53
(544.48)

102.30
(473.43)

172.83
(1,014.71)

264.18
(1,350.88)

0.1509

INR monitoring cost

7.57
(33.81)

19.14
(67.79)

14.86
(48.63)

4.85
(26.24)

19.98
(77.77)

20.76
(68.44)

0.0003

Total cost

2,945.2
(7,609.46)

3,055.47
(9,590.49)

1,826.7
(4,916.03)

2,507.53
(6,983.44)

2,432.01
(7,240.56)

2,839.94
(11,133.63)

0.4178
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Table 22: Mean log AF-related log costs stratified by trajectory groups
Variable

1. Rapid
decline
group,
Mean (SD)

2. Moderate
nonadherence
group,
Mean (SD)

3. Rapid decline
then increasing
adherence
group,
Mean (SD)

4. Moderate
decline
group,
Mean (SD)

5. Slow
decline
group,
Mean (SD)

6. perfect
adherence
group,
Mean (SD)

P-value

Inpatient cost

2.23
(4.64)

2.11
(4.53)

1.57
(4.00)

2.12
(4.52)

1.80
(4.24)

1.89
(4.33)

0.33

Outpatient cost

0.96
(2.61)

1.44
(3.12)

1.19
(2.79)

0.74
(2.33)

1.09
(2.70)

1.40
(3.05)

0.0013

INR monitoring cost

0.54
(1.48)

1.02
(2.06)

0.85
(1.93)

0.36
(1.24)

0.91
(1.98)

0.97
(2.07)

<0.0001

Total cost

3.02
(4.84)

3.40
(4.85)

2.76
(4.44)

2.70
(4.71)

2.99
(4.61)

3.17
(4.74)

0.23
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4.5 Sensitivity analysis

1. Sensitivity Analysis One: Three month follow-up period instead of one year
In the first sensitivity analysis, the follow-up period was defined as three months instead of
one year (as in the main analysis) to capture the short-term impact of warfarin adherence on
health outcomes. The number of beneficiaries who had been hospitalized in the first three
months after initiating warfarin therapy was 74 (2.3%). Similar to the main analysis, the AFrelated hospitalization events were most frequent in the “moderate decline” group (4.2%) and
least frequent in the “rapid decline then increasing adherence” group (0.93%) (Table 23).
The results for the Cox proportional hazards model for the three months follow up period
were similar to the main analysis (Table 24). There was no statistical difference in the
hazard ratio for AF-related hospitalization among the adherence groups. Only the
comorbidity index and the coverage gap remained significant in this sensitivity analysis.
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Table 23: Percentage of beneficiaries who had been hospitalization among adherence trajectories
Characteristics

Hospitalized
(2.28%)

Non-hospitalized
(97.72% )

1. Rapid decline group

2.12%

97.88%

2. Moderate non-adherence group

2.16%

97.84%

3. Rapid decline then increasing adherence group

0.93%

99.07%

4. Moderate decline group

4.20%

95.80%

5. Slow decline group

1.71%

98.29%

6.Perfect adherent group

2.73%

97.27%

Adherence trajectories (%)
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Table 24: Multivariable Cox proportional hazard models of adherence trajectories of warfarin
and risk of AF-related hospitalization in three months follow up period
Characteristics

AF-related hospitalization
HR (95%CI)

P-value

REF

REF

1. Rapid decline group

0.76 (0.34-1.70)

0.50

2. Moderate non-adherence group

0.80 (0.43-1.52)

0.50

3. Rapid decline then increasing adherence group

0.37 (0.09-1.55)

0.17

4. Moderate decline group

1.56 (0.75-3.22)

0.23

5. Slow decline group

0.64 (0.33-1.28)

0.21

Age

0.99 (0.95-1.03)

0.57

Gender (ref= Male)

1.10 (0.64-1.90)

0.73

REF

REF

Black

0.00 (0.00-.)

0.98

Others

1.91 (0.83- 4.38)

0.13

LIS eligibility

1.30 (0.76-2.22)

0.35

CCI

1.16 (1.03-1.32)

0.02

CHADS2-VASc score

1.18 (0.98-1.43)

0.09

Depression

0.73 (0.39-1.35)

0.31

Cognitive impairment and mental disorders

0.69 (0.29-1.64)

0.40

Number or chronic medications

1.01 (0.97-1.06)

0.61

Coverage gap

0.53 (0.30-0.93)

0.03

AC indicator

1.07 (0.65-1.76)

0.78

Trajectory group (ref= perfect adherent)

Race (ref= White)
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2. Sensitivity Analysis Two: Identify hospitalization events due to stroke or bleeding in all
diagnosis variables
In the second sensitivity analysis, the AF-related hospitalization events were identified using
all 25 diagnosis variables. The number of beneficiaries who had been hospitalized was 994
beneficiaries (30.62%). The AF-related hospitalization events were most frequent in the
“moderate non-adherence” group (32.91%) and least frequent in the “rapid decline then
increasing adherence” group (28.24%) (Table 25).
Similar to the main analysis, there was no statistical difference in the hazard ratio for AFrelated hospitalization among the adherence groups. The comorbidity index and the stroke
risk index remained statistically significant in this sensitivity analysis. (Table 26)
Table 25: Percentage of beneficiaries who had been hospitalization among adherence trajectories
Characteristics

Hospitalized
(30.62%)

Non-hospitalized
(69.38% )

1. Rapid decline group

30.69%

69.31%

2. Moderate non-adherence group

32.91%

67.09%

3. Rapid decline then increasing adherence group

28.24%

71.76%

4. Moderate decline group

29.01%

70.99%

5. Slow decline group

30.79%

69.21%

6.Perfect adherent group

29.42%

70.58%

Adherence trajectories (%)
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Table 26: Multivariable Cox proportional hazard model of adherence trajectories of warfarin and
risk of AF-related hospitalization-sensitivity analysis
Characteristics

AF-related hospitalization
HR (95%CI)

P-value

REF

REF

1. Rapid decline group

1.07 (0.86-1.33)

0.57

2. Moderate non-adherence group

1.16 (0.97-1.38)

0.10

3. Rapid decline then increasing adherence group

1.01 (0.76-1.34)

0.96

4. Moderate decline group

0.94 (0.72-1.22)

0.63

5. Slow decline group

1.08 (0.90-1.29)

0.43

Age

1.01 (1.00-1.02)

0.18

Gender (ref= Male)

1.07 (0.92-1.24)

0.36

REF

REF

Black

1.03 (0.77-1.38)

0.83

Others

0.98 (0.72-1.34)

0.90

LIS eligibility

1.01 (0.87-1.17)

0.91

CCI

1.25 (1.21-1.29)

<0.0001

CHADS2-VASc score

1.08 (1.03-1.14)

<0.01

Depression

1.14 (0.98-1.33)

0.10

Cognitive impairment and mental disorders

0.95 (0.77-1.18)

0.65

Number or chronic medications

0.99 (0.98-1.00)

0.26

Coverage gap

1.00 (0.86-1.15)

0.94

AC indicator

0.77 (0.67-0.88)

<0.01

Trajectory group (ref= perfect adherent)

Race (ref= White)
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Chapter 5: Discussion
This chapter discusses the results of the current study and addresses its strengths and limitations.

5.1 Specific aim 1
The current study applied the Group Based Trajectory Model (GBTM) to identify
adherence patterns of warfarin in AF patients during the first year after initiating treatment. The
study revealed that six trajectory groups best describe adherence patterns for warfarin therapy
among Medicare beneficiaries with AF. Based on the timing of warfarin discontinuation, the
identified groups are: 1) Rapid decline non-adherence group (11.5%, mean PDC: 0.22), 2)
moderate non-adherence group (24%, mean PDC: 0.56), 3) rapid decline then increasing
adherence group (6.8%, mean PDC: 0.85), 4) moderate decline non-adherence group (8.2%,
mean PDC: 0.51), 5) slow decline non-adherence group (24.3%, mean PDC: 0.84), and 6) perfect
adherence group (25.3%, mean PDC: 0.99).
In our study, GBTM shows an advantage over traditional adherence measures (i.e., PDC). For
example, when using an arbitrary cut-point of 80%, beneficiaries in the “6- perfect adherence”
group, “5- slow decline non-adherence” group, and “3- rapid decline then increasing adherence”
groups would be collapsed into one group and classified as perfectly adherent. In other words,
traditional measures such as PDC and MPR, would not differentiate between these three groups,
although, the beneficiaries in two groups, “5- slow decline non-adherence”, and “3- rapid decline
then increasing adherence”, would occasionally miss filling their warfarin prescriptions.
Moreover, this study provides some key information regarding patterns of warfarin
adherence. First, almost one fourth of elderly AF patients remained perfectly adherent during the
first year of warfarin treatment. On the other hand, almost 65% of new users of warfarin
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discontinued treatment at some point in the first year, as most of the identified adherence
trajectories show decline in their adherence behavior over time.
By running the GBTM, we were able to identify the time when patients are likely to be
non-adherent, thereby detecting the best timing for delivery of appropriate interventions. For
example, by exploring warfarin adherence trajectories we can recognize a clear separation
between the adherence trajectories in the fifth or sixth month after initiating warfarin treatment.
This separation between the adherence groups can provide insights for healthcare providers to
target patients with adherence interventions. For instance, based on our model, in the six months
follow-up visit for AF patients, the healthcare providers could focus on educating patients about
the importance of adherence to warfarin, try to address potential adherence barriers, and/or
identify any adverse events that may have caused them to discontinue warfarin. This is especially
true since a large proportion of AF patients are likely to show decline in their adherence to
warfarin after approximately six months of initiating treatment.
To our knowledge, this is the first study to utilize GBTM to identify the distinct patterns
of warfarin adherence in an AF Medicare population. In the previously published literature,
GBTM has been applied to classify adherence trajectories for different medications including
statins, oral hypoglycemic, antipsychotics, antihypertensive, and glaucoma medications.
Consistent with this literature, the current study showed that six trajectory groups best describe
longitudinal adherence patterns.32,44,45,48 The proportions of patients presented in our adherent
groups were similar to those of previous studies, in which most of the population was classified
in the “perfect adherence” group. However, Librero et. al, found that higher proportion of
patients (almost 60%) fell in the perfect adherent group than our study. This discrepancy could
be related to differences in the study population.69 Specifically, Librero et.al, studied the
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adherence trajectories for patients with Coronary Heart Disease (CHD) and included both the
incident and prevalent medication users, while in our study we only included incident users of
warfarin. Based on the literature, incident users are likely to be poorly adherent to their
medications compared to established patients.73,74
Compared to previous studies, there are some similarities in the identified patterns of
medication adherence. For example, “rapid decline non-adherence”, “moderate decline nonadherence”, and “perfect adherence” patterns were also identified in the previous
studies.32,34,44,47,48 In contrast, there were some differences in the intermediate trajectory groups.
Only Lo-Ciganic et. al, and Modi et. al, have identified similar trajectories of “moderate nonadherence” and “slow decline non-adherence” groups that were presented by our model.39,47 This
divergent finding may be due to many factors related to differences in disease characteristics,
study population, or study design.
In this study, we identified main characteristics and factors associated with the trajectory
groups. The factors that were found to be significantly associated with poor or intermediate
adherence patterns were race, CCI, CHADS2-VASc score, LIS, and being in Medicare coverage
gap. Compared to white patients, Hispanic, Asian, and North American Native patients were
more likely to have a moderate decline in their warfarin adherence in the first year of therapy,
which is consistent with other studies.41,44 Also, our study reveals that patients in the “moderate”
and “rapid decline non-adherence” groups had significantly higher comorbidities than patients in
the “perfect adherence” group. Several studies have also concluded that comorbidity is
associated highly with poor adherence.2,48
The characteristics identified in this study may guide healthcare providers and clinicians to
target patients who are more likely to have poor adherence to warfarin in the year following
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initiation. For example, for patients who are at higher risk of discontinuing warfarin, such as
Hispanic, Asian, and North American Native, the clinicians may need to educate them more
about the importance of adherence and facilitate their access to healthcare resources and system.
Moreover, by knowing characteristics of patients in each adherence trajectory we can
identify the best timing to deliver an intervention. For example, if the patient is likely to be in the
rapid decline group, as are patients with higher comorbidity, then clinicians may need to educate
those patients at the beginning of the warfarin treatment and try to identify potential barriers of
non-adherence such as cost, access to the healthcare system, or difficulty in managing disease
conditions.
Furthermore, some of these predictive factors are considered modifiable and can be used to
tailor appropriate interventions in order to improve patient adherence. For instance, in our study,
we found that patients who were not eligible for the LIS program were significantly more likely
to be in the rapidly and moderately declining groups compared to the perfect adherence group.
The LIS variable was used in this study as a proxy for patient income; however, LIS does not
reflect the exact socioeconomic status of the beneficiary. A Medicare beneficiary may not be
eligible for the LIS program but may still have a low income (i.e., income that does not reach the
Medicare threshold for LIS eligibility). This finding suggests that, although a patient’s income
may not be a modifiable factor, access to the healthcare system can be modifiable. Healthcare
providers or payers may need to improve regulation to facilitate access to the healthcare system
for the elderly population in order to enhance their medication adherence behavior and overall
health outcomes.
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5.2 Specific aim 2 and 3
In the current study, the effect of warfarin adherence trajectories on AF-related
hospitalization was assessed. We found that the risk of hospitalization was higher for the
beneficiaries in lower adherence groups compared to beneficiaries in the perfect adherence
trajectory. Patients with declining adherence and constantly moderate adherence had higher odds
of being hospitalized in the year following warfarin initiation compared to patients who were
well adherent to warfarin therapy.
In previous studies, adherence trajectories have been shown to have a significant
association with clinical outcomes for patients treated with statins, oral hypoglycemic
medications, anti-epileptics, endocrine therapy, and antipsychotics. In contrast, in our study we
did not observe any significant association between warfarin trajectory groups and AF-related
hospitalization.38,44,45,47-49 A number of reasons can explain this finding. First, this lack of an
association may be due to the lower number of hospitalization events captured in our data
compared to previous studies. Lo-Ciganic et. al. reported that the percentage of diabetes-related
hospitalizations/ED visits among the trajectory groups ranged between 14% to 19.5%, a range
sufficient to permit detection of significant differences between the trajectory groups.47
Conversely, the percentage of hospitalization events in our adherence groups ranges between 69%. Hence, due to the small proportion of beneficiaries that had experienced hospitalization
among the groups, we were not able to detect any significant differences. However, in the
sensitivity analyses we redefined hospitalization by using all the diagnosis variables, and the
number of hospitalization events increased, but we were still unable to observe a significant
difference in the hospitalization risk among trajectory groups. Second, the clinical outcome
measures in previous studies differ from those used in the current study. In our study we only
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looked at the risk of AF-related hospitalization. However, in other studies, the clinical outcomes
included ED visits with hospitalization events, and death. A study by MacEwan et. al, measured
the impact of trajectory group membership on psychiatrics ED visits separately from psychiatrics
hospitalization events and found significant differences in ED visits between trajectory groups.
However, the authors did not report any significant association with hospitalization events
between the trajectory groups.48 The third reason can be related to statistical issues. Each
parameter estimate has a standard error, which measures the variation of the sample parameter
from the population value. In the current study, the standard errors of the parameter estimates for
the hazard ratio, especially for the smaller size trajectory groups (group 3 and 4) were very large
and caused the confidence intervals to be wide. Hence, the hazard ratios for hospitalization were
not statistically significant. In other words, when we classified 3,246 beneficiaries into six
trajectory groups and used Cox proportional hazards modelling to compare the risk of
hospitalization among the groups, the variation associated with the parameter estimates of the
trajectory groups was found to be very high.
Although we did not observe a significant association between warfarin adherence
trajectories and AF-related hospitalization, we were still able to recognize the trend of
hospitalization risk between the trajectory groups. Based on the results, we can see that the
trajectory groups with declining adherence had a higher risk of being hospitalized in the year
following warfarin initiating compared to adherent groups, which is consistent with other
studies.44,45,47
Moreover, in this study we were able to quantify AF-related cost associated with each
trajectory group. To our knowledge, no previous study has assessed the economic impact of
adherence trajectory groups and compared between them. We found that there were significant
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differences between the monitoring costs and the outpatient costs among the adherence
trajectories. The beneficiaries in the “perfect adherence trajectory” had the highest INR
monitoring cost, which reflect the high number of anticoagulant clinic visits. Conversely, the
beneficiaries in the “rapidly decline” and “moderate decline” trajectories had the lowest INR
monitoring cost, and lowest number of anticoagulant clinic visits. This finding emphasizes the
important role of anticoagulant clinic access in improving patients’ adherence to warfarin. This
also is consistent with prior research.75
Although were not able to detect significant differences in the inpatient costs and the
overall direct medical costs among the trajectory groups, we were able to evaluate the trend in
the AF-related cost among different trajectory groups. Accordingly, we found that average
overall AF-related costs were higher for the beneficiaries with constantly moderate adherence or
rapidly declining adherence in their first year of warfarin treatment compared to beneficiaries in
the perfect adherence group.
These findings provide insight for healthcare providers and payers on trajectory groups
that are associated with higher cost and hence require more attention to improve their adherence
and promote lower overall healthcare costs.
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5.3 Strengths and limitations
To the best of our knowledge, this is the first study that has used GBTM to identify
adherence patterns for warfarin patients. The strength of our study is the use of the GBTM
approach in identifying the distinct adherence trajectories of warfarin in elderly AF patients.
Unlike traditional adherence measures, the GBTM accounts for the dynamic nature of the
adherence behavior over time, and can thus distinguish between different adherence patterns. In
the current study, we were able to identify six adherence trajectories for warfarin, which the PDC
and other traditional adherence measures cannot distinguish. For example, with the application of
a dichotomous PDC measure, patients in the “rapid decline non-adherence”, “moderate nonadherence” and “moderate decline non-adherence” groups will all be classified as non-adherent
although each group has a clearly different trajectory over time. Furthermore, we were able to
identify the predictive factors associated with each adherence trajectory. This can guide
clinicians and healthcare providers in identifying patients that are more likely to have poor
adherence to warfarin and target them with appropriate interventions. For example, a patient who
has a sustained moderate adherence over a long period of time, similar to patients in the
“moderate non-adherence” group, would benefit from a different intervention than a patient who
has decline in his adherence over time, such as patients in “moderate decline non-adherence”
group.
Moreover, in our study we used Medicare data, which is nationally representative and is a
good source of health information, especially for the elderly population. Further, recall bias was
reduced in our study as administrative data were used for warfarin refill information instead of
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self-reported surveys.
On the other hand, the study has several limitations. First, the selection of study
population depends on the accuracy of the reported ICD-9 codes in the Medicare dataset, which
may be subject to miscoding and misclassification, and hence could lead to inaccurate, though
conservative, results. We tried to address this limitation by requiring AF patients to have at least
one inpatient claim or two outpatient claims for AF in any of the 25 diagnosis variables in the
Medicare files. Second, we measured patients’ monthly adherence based on the refill data, a
method that may not capture actual consumption of warfarin. However, several studies have
shown a high correlation between refill data and patient consumption.76,77 Third, due to
limitations related to the data source, we were not able to examine the impact of some important
predictive factors, such as: social support, marital status, educational level, patients’ belief, and
medication-related adverse events. Also, Medicare data do not report the INR values and length
of time within the therapeutic range (TTR), which are important factors when assessing the
impact of warfarin therapy. The TTR reflect the quality of warfarin treatment, and hence can
drive adherence behavior. The TTR can play big role in explain warfarin adherence trajectories
and help in exploring reasons behind such trajectories. Moreover, we did not have information
regarding beneficiary income level, which could have influenced adherence trajectories.
However, we adjusted for this limitation, by using LIS eligibility as a proxy for low income, as
recommended by other investigators.44 Fourth, we were not able to capture prescriptions
dispensed outside of Medicare data (e.g., samples from physicians or medications purchased out
of pocket), especially as warfarin is available as a $4 generic and can be affordable. Fifth, as
warfarin is considered a critical drug (i.e., requiring regular dosage adjustment based on the INR
level, correlated with many drug/food interaction, and associated with higher risk of
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bleeding/stroke), the patient is likely to discontinue the treatment due to adverse events. For
example, if the patient’s adherence level was initially good and then dropped, this could be
related to unmeasured adverse events associated with warfarin use. However, in our study, we
were unable to distinguish between treatment discontinuation and non-adherence. Sixth, due to
the limited funding available for this study, we were only able to capture institutional resource
utilization and associated costs. That is, we were not able to include the carrier file claims (noninstitutional- physician office-based outpatient claims). Therefore, the resources utilized,
including access to anticoagulant clinics and associated costs were only reflective of the
institutional perspective (i.e., hospital outpatient claims).
Furthermore, some of the limitations of this study were related to the study’s design. For
example, it is likely that non-adherence behavior had an impact shortly after it occurred.
However, due to the time interval between the adherence measuring period and the outcome
period (one year follow up period) in the current study, we cannot affirm that AF-related
hospitalization is caused by adherence trajectories. However, we tried to address this limitation
in the sensitivity analysis, by testing a temporally closer three-months follow-up period, and the
results were essentially unchanged from the main analysis. Moreover, we did not account for the
hospitalization days when measuring monthly PDC. The hospitalization events occurring in the
identification period may have an impact on adherence behaviors, and hence can paly role in
describing adherence trajectories.
An important point to consider with the GBTM, is that there might be more than the six
identified warfarin adherence trajectories in the “real world”. However, as in the case with any
statistical approach, the goal of the GBTM is provide simplification of the real-world situation in
order to better understand the different adherence trajectories.
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Finally, our study was restricted to the elderly Medicare population having no HMO
coverage, so the results cannot be generalized to all AF patients treated with warfarin. Further
research is needed to identify adherence trajectories in a wider, more generalizable population
treated with warfarin.
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5.4 Conclusion and future directions
GBTM is a novel methodological approach that can be used to identify different patterns
of warfarin adherence in elderly AF patients. In our study, we were able to identify six distinct
adherence trajectories for new warfarin users that traditional adherence measures would not have
been able to detect. The application of the GBTM enabled us to visualize and better understand
changes in adherence behavior over time.
In this study, we also identified several significant predictors associated with each
trajectory group. These identified characteristics can enable healthcare providers to detect
patients who are more likely to become non-adherent to warfarin soon after treatment initiation
and determine the time when non-adherence may occur. Moreover, we evaluated the impact of
each adherence trajectory on subsequent AF-hospitalization and calculated associated costs for
each trajectory group. Hence, the findings of our study can help healthcare providers and payers
to target those groups of patients who might be associated with higher resource utilization and
healthcare costs.
The usefulness of applying GBTM in clinical practice is defined by its ability to identify
patients who are more likely to be in the poor or intermediate adherence groups, allowing
providers and health systems to target them with the suitable adherence interventions. Our
findings suggest that patients in the poor adherence groups may express different patterns of
adherence over time. This may indicate, hence, that such patients could benefit from different
interventions at different time points. Additionally, GBTM allows us to determine the timing of
onset of non-adherence, helping to identify the optimal times to deliver an intervention and
prevent further decline in adherence. For example, for patients who are likely to have rapid
decline in their adherence, it is better to target them with a suitable intervention at the beginning
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of treatment; while patients who might have slow decline in their adherence can be targeted with
a reminder intervention at later time (e.g., after six months). Overall, early identification of
patients at higher risk of non–adherence, and customization of suitable interventions for each
trajectory group of patients can help to better allocate resources and ultimately to improve patient
adherence and outcomes.
Further research is needed to evaluate the most effective adherence intervention for each
trajectory group. Moreover, there is increasing interest in the pharmacogenetics of warfarin
therapy in clinical practice. The metabolism of warfarin and its therapeutic effectiveness are
influenced by genetic variations. Pharmacogenetics can guide in estimating the appropriate dose
of warfarin. Hence, future research should examine the impact of pharmacogenetics effects on
warfarin adherence trajectories. Future research should also examine patterns of warfarin
adherence for longer periods of time (e.g., a five year follow up measuring period). Given that
warfarin is considered a life-long treatment for most AF patients, it would be of interest to
examine the long-term adherence patterns of warfarin patients. Moreover, further research is
needed to identify adherence patterns for warfarin in different populations and to compare
between these.
In conclusion, the results of this study illuminate important changes in adherence
behavior for the new warfarin users. GBTM is considered a promising methodological approach
that can be applied to the study of longitudinal adherence data and account for the dynamic
nature of adherence behavior in a better way than traditional adherence measures.
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Appendix A

Predisposing factors
Demographic:
• Age
• Gender
• Race
Social:
• Educational
level
Health belief
Treatment
characteristics:
• Complexity of
regimen
• Dosing
• INR monitoring
Disease characteristics:
• Cognitive
impairment
• Depression

Enabling factors
Personal:
• Insurance
• Income

Need factors
Perceived:
• Symptoms

Community:
• Social support

Evaluated:
• Illness severity

Figure A.1: Conceptual framework based on Andersen Behavioral model (ABM)
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Health behavior

Health outcome

(Nonadherence to
warfarin)

(ED visit/
hospitalization)

Appendix B
Table B.1: Percent change in Consumer price index (CPI) from 2009-2018

Medical care

2010

2011

2012

2013

2014

2015

2016

2017

3.62%

2.87%

3.43%

2.75%

2.42%

2.90%

2.98%

2.95% 2.21%

services
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2018

Appendix C

Figure C.1: Log minus log curve of the six trajectory groups and time to first hospitalization
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Appendix D

Figure D.1: Smoothed hazard ratio estimates using Schoenfeld residuals (Schres)
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Appendix E
Table E.1: Smoothed hazard ratio estimates using Schoenfeld residuals
Variable

Standard error

P-value

Intercept

Parameter
estimate
-0.02

0.04

0.63

Time to first hospitalization

0.0001

0.0002

0.57
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